

1
2
3 Application of Cell Painting
4 for chemical hazard evaluation
5 in support of screening-level chemical
6 assessments.
7

8 Jo Nyffeler^{1,2}, Clinton Willis¹, Felix R. Harris^{1,3}, MJ Foster^{1,3}, Bryant Chambers¹, Megan Culbreth¹, Richard
9 E. Brockway^{1,3}, Sarah Davidson-Fritz¹, Daniel Dawson¹, Imran Shah¹, Katie Paul Friedman¹, Dan Chang¹,
10 Logan J. Everett¹, John F. Wambaugh¹, Grace Patlewicz¹, Joshua A. Harrill^{1,*}

11 ORCIDs:

12 Nyffeler: <https://orcid.org/0000-0002-6155-9743>
13 Willis: <https://orcid.org/0000-0002-4996-1780>
14 Harris: <https://orcid.org/0000-0002-0256-7452>
15 Foster: NA
16 Chambers: <https://orcid.org/0000-0002-2233-3207>
17 Culbreth: <https://orcid.org/0000-0002-3101-1541>
18 Brockway: NA
19 Davidson-Fritz: <https://orcid.org/0000-0002-2891-9380>
20 Dawson: <https://orcid.org/0000-0001-9622-4495>
21 Shah: <https://orcid.org/0000-0003-0808-0140>
22 Paul Friedman: <https://orcid.org/0000-0002-2710-1691>
23 Chang: <https://orcid.org/0000-0001-7561-2747>
24 Everett: <https://orcid.org/0000-0002-9713-6099>
25 Wambaugh: <https://orcid.org/0000-0002-4024-534X>
26 Patlewicz: <https://orcid.org/0000-0003-3863-9689>
27 Harrill: <https://orcid.org/0000-0003-4317-6391>
28

29 Affiliations:

30 ¹ Center for Computational Toxicology & Exposure, Office of Research and Development, US
31 Environmental Protection Agency, Durham, NC 27711

32 ² Oak Ridge Institute for Science and Education (ORISE) Postdoctoral Fellow, Oak Ridge, TN, 37831

33 ³ Oak Ridge Associated Universities (ORAU) National Student Services Contractor, Oak Ridge, TN, 37831

34 * Corresponding Author

35 Joshua A. Harrill
36 Center for Computational Toxicology and Exposure (CCTE)
37 U.S. Environmental Protection Agency
38 109 TW Alexander Drive, Research Triangle Park, NC 27709
39 harrill.joshua@epa.gov

40 **Running title:** Bioactivity Screening of ToxCast Chemicals in U-2 OS with HTPP.

41 **Key words:** High-throughput phenotypic profiling, Cell Painting, concentration-response, computational
42 toxicology

43

44 Abstract

45 'Cell Painting' is an imaging-based high-throughput phenotypic profiling (HTPP) method in which
46 cultured cells are fluorescently labeled to visualize subcellular structures (i.e., nucleus, nucleoli,
47 endoplasmic reticulum, cytoskeleton, Golgi apparatus / plasma membrane and mitochondria) and to
48 quantify morphological changes in response to chemicals or other perturbagens. HTPP is a high-
49 throughput and cost-effective bioactivity screening method that detects effects associated with many
50 different molecular mechanisms in an untargeted manner, enabling rapid *in vitro* hazard assessment for
51 thousands of chemicals. Here, 1201 chemicals from the ToxCast library were screened in concentration-
52 response up to ~100 μ M in human U-2 OS cells using HTPP. A phenotype altering concentration (PAC)
53 was estimated for chemicals active in the tested range. PACs tended to be higher than lower bound
54 potency values estimated from a broad collection of targeted high-throughput assays, but lower than
55 the threshold for cytotoxicity. *In vitro* to *in vivo* extrapolation (IVIVE) was used to estimate administered
56 equivalent doses (AEDs) based on PACs for comparison to human exposure predictions. AEDs for
57 18/412 chemicals overlapped with predicted human exposures. Phenotypic profile information was also
58 leveraged to identify putative mechanisms of action and group chemicals. Of 58 known nuclear receptor
59 modulators, only glucocorticoids and retinoids produced characteristic profiles; and both receptor types
60 are expressed in U-2 OS cells. Thirteen chemicals with profile similarity to glucocorticoids were tested in
61 a secondary screen and one chemical, pyrene, was confirmed by an orthogonal gene expression assay as
62 a novel putative GR modulating chemical. Most active chemicals demonstrated profiles not associated
63 with a known mechanism-of-action. However, many structurally related chemicals produced similar
64 profiles, with exceptions such as diniconazole, whose profile differed from other active conazoles.
65 Overall, the present study demonstrates how HTPP can be applied in screening-level chemical
66 assessments through a series of examples and brief case studies.

67

68 Abbreviations

69	AED	administered equivalent dose
70	AGP	actin, golgi, plasma membrane
71	AR	androgen receptor
72	ATRA	all trans-retinoic acid
73	BER	bioactivity exposure ratio
74	BMC	benchmark concentration
75	BMR	benchmark response
76	Cl_{int}	intrinsic hepatic clearance
77	CCTE	Center for Computational Toxicology and Exposure
78	DMEM	Dulbecco's Modified Eagle Medium
79	DMSO	dimethyl sulfoxide
80	EC50	effective concentration 50%
81	ER	estrogen receptor
82	FPR	false positive rate
83	F_{up}	fraction unbound in plasma
84	GR	glucocorticoid receptor
85	GRE	glucocorticoid response element
86	HTPP	high-throughput phenotypic profiling
87	HTTr	high-throughput transcriptomics
88	HTS	high-throughput screening
89	IVIVE	<i>in vitro</i> to <i>in vivo</i> extrapolation
90	LOEC	lowest observed effect concentration
91	$\log K_{oA}$	octanol air partition coefficient
92	MAD	median absolute deviation
93	MOA	mechanism-of-action
94	Mito	mitochondria
95	NAMs	new approach methods
96	nCC	normalized cell count
97	NR	nuclear receptor
98	nMAD	normalized median absolute deviation
99	PAC	phenotype altering concentration
100	PPAR	peroxisome proliferator-activated receptor
101	PBS	phosphate-buffered saline
102	PMI	pointwise mutual information
103	POD	point-of-departure

104	QSPR	quantitative structure-property relationships
105	RA	retinoic acid
106	RAR	retinoic acid receptor
107	RT-qPCR	reverse transcription quantitative polymerase chain reaction
108	RXR	retinoid X receptor
109	SD	standard deviation
110	SRP	stress response pathways
111	USEPA	United States Environmental Protection Agency
112		

113 Introduction

114 'Cell Painting' is an imaging-based profiling method in which cultured cells are fluorescently
115 labeled to visualize subcellular structures (i.e., nucleus, nucleoli, endoplasmic reticulum, cytoskeleton,
116 Golgi apparatus / plasma membrane and mitochondria) and changes to the morphology (e.g., their
117 phenotypic appearance) are quantified (Gustafsdottir *et al.*, 2013). Many other bioassays are targeted;
118 that is, they are designed to measure specific, expected effects on a discrete molecular target or
119 biological process. In comparison, Cell Painting is a profiling assay and thus untargeted, meaning that a
120 broad range of biological effects can be observed and evaluated. The method is high throughput and
121 more cost effective than other molecular profiling methods, such as transcriptomics or panels of
122 targeted assays (Chandrasekaran *et al.*, 2021). For these reasons, Cell Painting has been used in many
123 applications, including by the pharmaceutical industry for lead hopping, to establish chemical screening
124 libraries with diverse biological activities, or for functional genomic screens (Caicedo *et al.*, 2016).
125 Different perturbations can result in different phenotypes, which several groups have leveraged to
126 predict outcomes of *in vitro* bioassays (Simm *et al.*, 2018; Hofmarcher *et al.*, 2019; Way *et al.*, 2021),
127 mechanism-of-action (MOA) (Caie *et al.*, 2010; Woehrmann *et al.*, 2013; Ramm *et al.*, 2019; Warchal *et al.*,
128 *et al.*, 2019; Trapotsi *et al.*, 2021) or *in vivo* organ toxicity (Su *et al.*, 2016; Ramm *et al.*, 2019).

129 The Center for Computational Toxicology and Exposure (CCTE) at the United States
130 Environmental Protection Agency (USEPA) became interested in using the Cell Painting assay for
131 bioactivity screening of chemicals because of its cost-effectiveness (Hughes *et al.*, 2011; Svenningsen
132 and Poulsen, 2019; Chandrasekaran *et al.*, 2021; Marin Zapata *et al.*, 2023) and its broad applicability to
133 different cell types. Scientists at CCTE proposed a tiered testing strategy whereby the first tier comprises
134 *in silico* predictions and *in vitro* bioactivity screening of large chemical collections using two high-
135 throughput profiling methods: image-based high-throughput phenotypic profiling (HTPP) with the Cell
136 Painting assay and high-throughput transcriptomics (HTTr) with targeted RNA-Seq (Thomas *et al.*, 2019).
137 The second tier consists of targeted high-throughput screening (HTS) assays to confirm biological activity
138 observed in Tier 1, followed by higher order tiers including more complex low-throughput systems such
139 as organotypic models and microphysiological systems. The goal of the first tier is to rapidly generate
140 information about the concentration at which a chemical exerts bioactivity, as well as its putative
141 mechanisms. The first-tier screening data from HTPP (and HTTr) could be used in a variety of ways to
142 inform chemical risk assessment, including prioritization of chemicals based on the overlap of biological
143 activity with human exposure predictions, inference of molecular MOA by comparison to reference

144 chemicals and grouping of chemicals based on similarities in bioactivity profiles to inform chemical read-
145 across.

146 While other groups notably in the pharmaceutical sector are mostly interested in drug-like
147 chemicals that have one (or a few) specific target(s), the research at CCTE is more focused on
148 characterizing the putative bioactivity of chemicals found in the environment, such as pesticides,
149 herbicides and industrial chemicals in order to inform chemical risk assessment. Such chemicals were
150 typically not designed to have biological activity in humans and in many cases, human health hazard has
151 been incompletely characterized. Moreover, researchers using Cell Painting (or similar profiling assays)
152 in phenotypic drug discovery are often focused on a particular phenotype, or transition between
153 phenotypes, such as reversion of diseased cells to a “healthy” phenotype (Chandrasekaran *et al.*, 2021).
154 In contrast, bioactivity screening of environmental chemicals requires an approach that is capable of
155 measuring the vast array of unknown phenotypes these chemicals may produce in order to detect any
156 type of biological effects. Additionally, when screening environmental chemicals, there is a priority to
157 avoid false negatives, while a certain number of false positives are acceptable in this first testing tier
158 (Nyffeler *et al.*, 2021).

159 We previously adapted the HTPP approach to be compatible with our available microfluidic
160 instruments and screened 462 chemicals in human U-2 OS osteosarcoma cells (Nyffeler *et al.*, 2020).
161 Upon comparison to mammalian *in vivo* studies, we found that HTPP effect values were lower or
162 comparable to *in vivo* effect values for 68% of chemicals. We further conducted a small study where we
163 profiled U-2 OS cells with both HTPP and HTTr and demonstrated that for one model compound, all-
164 trans retinoic acid (ATRA), a characteristic cellular phenotype co-occurs with transcriptional changes
165 specific to activation of the retinoic acid receptor signaling pathway (Nyffeler *et al.*, 2022).

166 In the present study, we screened 1201 unique chemicals from the ToxCast chemical library
167 (Richard *et al.*, 2016) in concentration-response mode. We then compared how potency estimates from
168 HTPP related to those from other *in vitro* assays and provided an example of how HTPP can be used for
169 screening-level assessments via the bioactivity exposure ratio (BER) approach. For the first time, we
170 leverage the broad phenotypic information collected with HTPP to identify putative MOAs for
171 environmental chemicals in a human-derived cell model and group chemicals based on similarities in
172 biological activity. These concepts are demonstrated using multiple examples.

173 Materials and Methods

174 Materials

175 Materials and reference chemicals were purchased from various suppliers (Table S1). Lists of
176 screened chemicals are provided as supplementary documents (File S1-S2).

177 Cell culture

178 U-2 OS human osteosarcoma cells (HTB-96®, Lot: 64048673, ATCC) were expanded to internal
179 passage number 6 (P6) as described previously (Nyffeler *et al.*, 2020). For the purposes of this study, a
180 subsequent stock of cells was expanded and cryopreserved at P8 using those same methods. Culture
181 media consisted of Dulbecco's Modified Eagle Medium (DMEM) with 10% heat-inactivated fetal bovine
182 serum and penicillin/streptomycin/glutamine. The primary screen was performed with cells expanded
183 from P8 to P10. Follow-up experiments were conducted using P9 cells. Cells were plated at 3000
184 cells/well in 40 µL media or 9000 cells/well in 120 µL media for 384-well and 96-well plates, respectively,
185 as described previously (Nyffeler *et al.*, 2022).

186 Chemical treatment

187 For screening in 384-well format, all test chemicals were received as solutions in dimethyl
188 sulfoxide (DMSO) from the USEPA ToxCast library management contractor (Evotec, Princeton, NJ).
189 Solutions were 20 mM or the highest concentration soluble in DMSO not exceeding 20 mM. An 8-point
190 dilution series of each test chemical was prepared in DMSO using a uniform dilution scheme (half log₁₀-
191 spacing). The dilutions were prepared as 200x the desired nominal test concentrations corresponding to
192 0.03 to 100 µM for chemicals received as 20 mM stocks. Reference chemicals (e.g., dexamethasone,
193 etoposide, ATRA, staurosporine and trichostatin A) were purchased as neat chemicals and solubilized in
194 DMSO at CCTE laboratories. Dilution series of the first three reference chemicals were prepared as
195 described for test chemicals. Chemical treatments were dispensed 24 h after cell seeding using a
196 LabCyte Echo 550 acoustic dispenser (Beckman-Coulter, Indianapolis, IN) and randomized plate layouts
197 (Fig. S1) as described previously (Nyffeler *et al.*, 2020; Nyffeler *et al.*, 2022). In brief, 200 nL of 200x stock
198 was dispensed into 40 µL of media in the test wells.

199 For treatments in 96-well plates, 20 µL of media was removed from the cell culture well. Then
200 750 nL of chemical was dispensed into an empty 384-well plate using the LabCyte Echo 550 acoustic
201 dispenser, manually filled with 25 µL cell culture media and 20 µL of this manually transferred onto the

202 cells. The final concentration of DMSO in test wells was 0.5% for all experiments, regardless of plate
203 format. The vehicle control treatment for all experiments was 0.5% DMSO.

204 [Experimental design for primary screen](#)

205 In the primary screen, 1218 chemical samples comprising 1201 unique chemicals were tested at
206 8 concentrations each, with one technical replicate and four biological replicates (i.e., independent cell
207 cultures). All tested chemicals are listed in [File S1](#) and on the EPA CompTox Chemicals Dashboard
208 (https://comptox.epa.gov/dashboard/chemical-lists/HTPP2023_U2OS_SCREEN). The 1218 chemicals
209 were distributed among 29 dose plates. Each dose plate contained up to 42 test chemicals and three
210 reference chemicals (dexamethasone, etoposide, ATRA) at 8 concentrations in half-log₁₀ spacing, as well
211 as three wells of a reference chemical (trichostatin A) and three wells of a cell viability positive control
212 chemical (staurosporine) at a single concentration (1 μM), and eighteen wells of vehicle control (0.5%
213 DMSO). Each dose plate was used to treat four assay plates across four biological replicates (i.e.,
214 independent cultures). A set of four assay plates receiving the same group of test chemicals is referred
215 to as a 'plate group' ([Fig S1](#)).

216 [High-throughput phenotypic profiling assay \(HTPP\)](#)

217 **Fluorescent labeling**

218 Phenotypic profiling of cells was performed using the 'Cell Painting' method (Bray *et al.*, 2016).
219 Fluorescent labeling was performed exactly as described in Nyffeler *et al.* (2020). In brief, the nucleus,
220 nucleolus, endoplasmic reticulum, actin cytoskeleton, Golgi apparatus / plasma membrane and
221 mitochondria were visualized with Hoechst-33342, SYTO14, Alexa Fluor™ 488 Concanavalin A conjugate,
222 Alexa Fluor™ 568 Phalloidin conjugate, Alexa Fluor™ 555 Wheat Germ Agglutinin conjugate and
223 MitoTracker DeepRed, respectively.

224 **Image acquisition & feature extraction**

225 Fluorescent images were acquired using an Opera Phenix High Content Screening System and
226 Harmony® software (v4.9). Five distinct fields-of-view were acquired with a 20× water immersion
227 objective in confocal mode exactly as described in Nyffeler *et al.* (2020). A total of 1300 features per cell
228 were extracted.

229 **Aggregation and normalization**

230 For each feature, data were normalized to vehicle-control treated cells using the median and
231 median absolute deviation (MAD) as described previously (Nyffeler *et al.*, 2020) and aggregated to the

232 well-level by computing the median of all cells in that well. Well-level data were scaled further by using
233 the vehicle control wells of the corresponding plate group (typically 96 wells), but in slight modification
234 from previous reports (Nyffeler *et al.*, 2022); the mean and standard deviation (SD) were used instead of
235 the median and normalized MAD. These scaled values were used for concentration-response modeling
236 and graphical representations.

237 **Cell viability analysis**

238 Cell counts from the HTPP assay plates were used to evaluate cell viability and cytostasis in the
239 present study. This differs from our previous studies (Nyffeler *et al.*, 2020; Willis *et al.*, 2020) where
240 separate assay plates labeled with Hoechst-33342 and propidium iodide were used to assess
241 cytotoxicity. In the present study, normalized cell counts (nCC) were calculated by dividing the number
242 of cells in each treatment well by the average number of cells in vehicle control wells on the same plate.
243 Concentration-response modeling of nCC was performed using *tcplfit2*. The benchmark response was
244 set at 50% and a cell viability benchmark concentration (CV BMC) was determined. For chemicals with a
245 CV BMC, the lowest test concentration above the CV BMC was defined as the lowest observed effect
246 concentration (CV LOEC) and the highest test concentration below the CV BMC was defined as the no
247 observed effect concentration (CV NOEC). Treatments that produced a greater than 50% decrease in
248 nCC were excluded from analysis of HTPP data.

249 [Concentration-response analysis of HTPP data](#)

250 **Generation of null chemicals**

251 In order to estimate a false positive rate (FPR), a synthetic data set was created consisting of
252 responses of the two lowest concentrations of the tested chemicals. Only responses from chemicals
253 with at least 6 non-cytostatic concentrations were eligible. The responses were randomly assigned to
254 the null chemicals on a per plate basis. In this manner, 10 null chemicals with 8 concentrations each and
255 four biological replicates could be generated for each plate group, resulting in a total of 290 null
256 chemicals. These null chemicals were treated exactly as the test chemicals for concentration-response
257 modeling.

258 **Mahalanobis distance calculation**

259 Two separate Mahalanobis distance modeling approaches were used to reduce the information
260 from the 1300 features to fewer dimensions for concentration-response modeling as described
261 previously (Nyffeler *et al.*, 2021). For the 'Global Mahalanobis' approach, one distance value was

262 generated for each treatment from the combined 1300 features. For the 'Category-level Mahalanobis'
263 approach, one distance value was generated for each of 49 feature categories for each treatment. A
264 feature category consists of multiple features generated from the same channel, organelle and analysis
265 module. Each of the 1300 features maps to one of 49 categories.

266 **Concentration-response modeling**

267 Mahalanobis distances were used for concentration-response modeling using the R package
268 *tpclfit2* (v0.1.0) (Sheffield *et al.*, 2021) as described previously (Nyffeler *et al.*, 2021; Nyffeler *et al.*, 2022)
269 with minor modification. First, cell count information was used to remove overtly cytostatic
270 concentrations, defined as those that caused a > 50% reduction in nCC compared to vehicle control.
271 Then Mahalanobis distance data were modeled using nine different functions (constant, Hill, poly1,
272 poly2, power, exp2, exp3, exp4, exp5) and setting the cutoff to 1 standard deviation (SD). Chemicals for
273 which the modeled responses did not exceed the cutoff were only modeled with the constant model
274 and thus were deemed inactive. The ~~benchmark concentration~~ BMC was defined as the concentration at
275 which the response exceeded the benchmark response (BMR) of 1 SD. BMCs more than half an order of
276 magnitude below the lowest tested concentration were set to that value. For the 'Category-level
277 Mahalanobis' approach, only curves with a hitcall probability of > 0.9 were considered as active; for the
278 'Global Mahalanobis' approach no additional restrictions were set.

279 **Hit identification**

280 Chemicals were considered phenotypically active if a BMC could be identified with either the
281 'Global Mahalanobis' approach or for at least one category using the 'Category-level Mahalanobis'
282 approach. The phenotype altering concentration (PAC) was defined as the lower of the Global BMC or
283 most sensitive Category-level BMC.

284 [Comparison of phenotypic profiles](#)

285 **Feature selection**

286 Of the 1300 acquired features, only a subset was used to compare phenotypic profiles. Features
287 were eliminated in three steps: (1) One feature was excluded that always gave a constant value and thus
288 did not provide any information; (2) 716 features were excluded as their response across biological
289 replicates had low correlation (Pearson correlation ≤ 0.5), thus indicating low reproducibility, similar as
290 described in Woehrmann *et al.* (2013); and (3) the remaining 583 features underwent stepwise feature
291 elimination (Bray *et al.*, 2016; Warchal *et al.*, 2019). In the process of feature elimination, the feature
292 pair with the highest correlation was identified, one of the two features removed, then this process was

293 repeated until all remaining features were correlated less than a set threshold value (Kendall correlation
294 < 0.75). This procedure resulted in 289 selected features (listed in [File S3](#)). A detailed description of the
295 procedure is provided in the supporting information ([Fig. S2](#)).

296 **HTPP profile generation and evaluation of biological similarity**

297 Similarity of biological responses was then calculated by comparing phenotypic profiles using
298 the 289 selected features. First, all bioactive concentrations of test chemicals were identified (i.e., above
299 the PAC and below the CV LOEC). Second, the lowest test concentration that resulted in a reproducible
300 profile (defined in [Fig. S3](#)) was identified. As the PAC marks the onset of bioactivity, it may be that a
301 robust reproducible profile is only observable at a slightly higher concentration. Third, after finding the
302 lowest concentration with a reproducible profile, up to two higher concentrations were selected, if they
303 were still below the CV LOEC. These profiles were then modified by setting values that fall within [-1,1]
304 to 0, to reduce noise. Profiles were then compared using Kendall correlation. This procedure resulted in
305 multiple correlation values for each chemical pair; thus, these data were further summarized by
306 retaining the highest correlation value for each chemical pair. A detailed description is provided in the
307 supporting information ([Fig. S3](#)).

308 [Combination of HTPP results with other data streams](#)

309 **Generation of chemical structural features and calculation of structural similarity**

310 Chemical structure features aim to represent molecules in machine-readable notation, such as
311 binary or categorical descriptors. Different approaches exist that each have advantages and
312 disadvantages. In the present study, the following descriptors were used to explore whether chemicals
313 with structural similarities produce similar phenotypic profiles in U-2 OS cells:

314 (1) ToxPrint chemotypes consist of a predefined library of 729 sub-structural features designed
315 to encapsulate a broad range of chemical atoms and scaffolds, which were developed by Altamira and
316 Molecular Networks under contract by the US Food and Drug Administration (Yang *et al.*, 2015). Whilst
317 the binary molecular fingerprint is generated for the set of chemicals utilizing the publicly available
318 ToxPrint chemotype feature set (<https://toxprint.org>) and the ChemoTyper software
319 (<https://chemotyper.org/>), given the large number of substances being profiled, the commercial
320 command line version of CORINA Symphony application licensed from Molecular Networks was used.
321 ToxPrint chemotypes were generated for 1173 chemicals.

322 (2) ClassyFire (Djoumbou Feunang *et al.*, 2016) was used to generate structural features (i.e.,
323 substituents) identified through the application's rules-based approach that utilizes its comprehensive
324 chemical structure and structural feature hierarchical chemical taxonomy (ChemOnt) to assign chemical
325 compounds to 4825 categories covering both organic and inorganic chemistries. The chemical taxonomy
326 consists of up to 11 levels (i.e., Kingdom, SuperClass, Class, SubClass, etc.). The terms Kingdom,
327 SuperClass, Class, and SubClass denote the first, second, third and fourth levels of the chemical
328 taxonomy, respectively, where the top level (Kingdom) refers to two distinct classes of chemistries – i.e.,
329 organic and inorganic compounds. Each subsequent level in the chemical taxonomy consists of more
330 specific chemical categories and hence, more specific and recognizable structural features (i.e., nodes)
331 as one goes down the taxonomic tree. ClassyFire also returns a list of chemical substituents (i.e.,
332 structural features within a corresponding chemical category such as functional groups, substructures or
333 motifs) contained in the chemical structure. Utilizing the molecules' InChIKeys ([https://iupac.org/who-
334 we-are/divisions/division-details/inchi/](https://iupac.org/who-we-are/divisions/division-details/inchi/)), a list of chemical substituents was generated using the
335 ClassyFire web API (<http://classyfire.wishartlab.com/>) to programmatically access the stored pre-
336 processed data as a query lookup. The keywords in the column 'substituents' were used to generate
337 binary fingerprints (presence/absence of a given keyword). Fingerprints were available for 1171
338 chemicals and 1010 features were present in at least one chemical.

339 (3) The OECD Toolbox (v4.4.1) (Dimitrov *et al.*, 2016) was used to profile the set of chemicals
340 through all available profiling schemes. There are several types of 'profilers' in the Toolbox to facilitate
341 the categorization process. The profilers are grouped into different types from predefined, general
342 mechanistic, endpoint specific, empiric and toxicological. These profilers are effectively structural alert
343 schemes that may assign a chemical into a predefined chemical category. Keywords in the columns
344 'Organic.functional.groups' (general), 'Organic.functional.groups.nested' (nested),
345 'Organic.functional.groups.Norbert.Haider.checkmol' (NH), 'Organic.functional.groups.US.EPA' (USEPA)
346 and 'US.EPA.New.Chemical.Categories' (newCat) were used to generate binary fingerprints
347 (presence/absence of a given keyword). The term in brackets indicates the prefix added to the keyword
348 for graphical representation. Fingerprints were available for 1151 chemicals and 669 features were
349 present in at least one chemical. The Organic.functional.groups (OFG) profiler was developed by LMC in
350 2012 and comprises 534 categories. The OFG profiler is subdivided into two types, OFG and OFG nested.
351 The difference is that OFG displays all functional groups present in a chemical structure whereas OFG
352 nested does not show functional groups that are nested in larger ones e.g., an aldehyde group would be
353 nested in the carboxylic group and is not shown with OFG nested. The OFG NH was created on the basis

354 of 204 organic functional groups recognized by the CheckMol program that had been developed by Dr.
355 Norbert Haider of the University of Vienna, Austria. The OFG USEPA comprises 466 categories developed
356 from the 645 structural fragments and correction factors underpinning the EPA KOWWIN fragment
357 library in the EPISuite program. The EPA New Chemical Categories profiler aims to reproduce the original
358 categories cited in the New Chemicals Program Chemical Categories, which was last revised in 2010 (see
359 <https://www.epa.gov/reviewing-new-chemicals-under-toxic-substances-control-act-tsca/chemical->
360 [categories-used-review-new](https://www.epa.gov/reviewing-new-chemicals-under-toxic-substances-control-act-tsca/chemical-categories-used-review-new)). Not all categories were implemented since a handful were based on
361 physical considerations and did not include specific structure-based rules. The newCat profiler comprises
362 66 categories.

363 The 729 ToxPrints were used to calculate structural similarity of chemicals as this set of
364 fingerprints describes more detailed features as opposed to the other two methods. Structural similarity
365 was calculated using Jaccard/Tanimoto similarity (Jaccard, 1902) with the function *jaccard* from the R
366 package *jaccard*. All structural feature sets were used for the enrichment analysis described below in
367 '*Enrichment of structural and biological properties within phenotypic clusters*'.

368 **Bioactivity-Exposure-Ratio (BER) analysis**

369 For all chemicals, the molecular weight was obtained from the CompTox Chemicals Dashboard,
370 and physicochemical properties were predicted using quantitative structure-property relationships
371 (QSPRs) provided by OPERA v2.6 (Mansouri *et al.*, 2018). Using these properties, chemical-specific
372 values for the fraction unbound (F_{up}) and internal clearance (Cl_{int}) were predicted using the QSPR models
373 from Dawson *et al.* (2021). A total of 1041/1205 chemicals were in the applicability domain of the
374 Dawson *et al.* 2021 QSPR models. Of those, 412 were active in the HTPP assay. For these 412 chemicals,
375 the administered equivalent dose (AED in units of mg/kg bodyweight/day) was calculated using the *httk*
376 R package (v2.2.2) (Pearce *et al.*, 2017) as described previously (Paul-Friedman *et al.*, 2019; Nyffeler *et*
377 *al.*, 2020; Breen *et al.*, 2021), based on the predicted F_{up} , Cl_{int} , and octanol-water partitioning values.
378 Briefly, oral equivalents were calculated for human species (using function "calc_mc_oral_equiv") with
379 restrictive clearance set to 'true'. Population variability was simulated using Monte Carlo (Ring *et al.*,
380 2017) and the 5th percentile (i.e., most sensitive) of the population distribution was considered as the
381 HTPP AED.

382 General population human exposure predictions (mg/kg bodyweight/day) were obtained from
383 the SEEM3 consensus exposure model (Ring *et al.*, 2019) for all but one chemical. SEEM3 provides
384 distributions of plausible daily intake rates and the upper 95th percentile limit on the estimated median

385 population intake was used. The BER was calculated as the ratio of the bioactivity estimate (HTPP AED)
386 and the SEEM3 exposure predictions as described (Paul-Friedman *et al.*, 2019; Canada, 2021). A
387 $\log_{10}(\text{BER}) < 0$ indicates that the chemical was bioactive at or below the predicted exposures while a
388 $\log_{10}(\text{BER}) > 0$ indicates that bioactivity was detected at or above the predicted exposures. More positive
389 values of $\log_{10}(\text{BER})$ indicate a larger margin between those two measures, respectively.

390 **Comparison to targeted *in vitro* assay results**

391 *In vitro* bioactivity data from the US EPA ToxCast program (Dix *et al.*, 2007; Judson *et al.*, 2010)
392 were obtained from the database *invitrodb* (version 3.4,
393 <https://doi.org/10.23645/epacomptox.6062623.v7>) and summarized as detailed in [Suppl. Fig S4](#). The
394 database contains potency estimates and activity calls ('hitcall') for chemical x assay endpoint pairs. For
395 chemicals tested more than once in a given assay, results were averaged using a weighted approach that
396 gives less weight to concentration-response curves with more caution flags, as caution flags tend to be
397 indicative of less reliable data/curve fits. Subsequently, an *in vitro* point-of-departure (POD) was
398 calculated from the lowest three potency estimates (i.e., benchmark concentration, BMC) out of all
399 active assays for a given chemical, again by using a weighted average using the number of caution flags
400 as weights.

401 For comparison with HTPP, only chemicals that were run in at least 400 ToxCast assay endpoints
402 were included (n=1075 chemicals). A chemical was deemed active in the ToxCast battery if it was active
403 in at least 3 assay endpoints, which was the case for 896 chemicals.

404 A subset of ToxCast assay endpoints (n=75) were annotated as relating to cytotoxicity and cell
405 health and were used to calculate a 'burst' estimate, i.e., a lower bound potency measure for impact on
406 general cell health using the function *tcp/CytoPt* of the *tcpI* package (version 2.0.2). Only chemicals that
407 were run in at least 40 'burst' assays were included (n=1071 chemicals). A chemical was deemed active
408 in the 'burst' assays if the lower bound potency estimate was < 1000 μM .

409 **Annotation of chemicals to known MOA**

410 For all chemicals that were active in the screen, annotations were retrieved from RefChemDB
411 (Judson *et al.*, 2019). Only entries for nuclear receptors (NRs) as targets were considered. Fifty-six
412 chemicals had a support of five or more for one of 21 NRs. As some chemicals were annotated to more
413 than one receptor family, this list was manually curated to retain only the most significant target for

414 each chemical. Despite these efforts, two chemicals could not be resolved and were assigned to two
415 receptor families.

416 **Enrichment of structural and biological properties within phenotypic clusters**

417 To cluster the phenotypic profiles of all active chemicals (n=547), only the profile from the
418 highest of the three lowest active concentrations was selected. For these profiles (consisting of the 289
419 selected features), similarity was calculated using the function *get_dist* from the package *factoextra*
420 (v1.0.7) with the option *method="kendall"* followed by clustering with the function *hclust* from the *stats*
421 package (v.3.6.2). The resulting tree was then cut into 15 clusters.

422 *Enrichment of chemical fingerprints:* Chemical fingerprints were generated with ToxPrints,
423 ClassyFire, and the OECD Toolbox as described in '*Generation of chemical structural features and*
424 *calculation of structural similarity*'. A Chi-squared test was performed comparing the number of
425 chemicals with/without a feature and their presence/absence in a given cluster. The p-value was
426 calculated with the function *chisq.test* from the *stats* package with options *correct=TRUE* and
427 *simulate.p.value=F*.

428 *Enrichment of activity in ToxCast/Tox21 bioassays:* Activity data was summarized to binary
429 hitcalls as explained in '*Comparison to targeted in vitro assay results*'. A total of 1191 chemicals had
430 activity data for at least one bioassay. A Chi-squared test was performed comparing the number of
431 chemicals that were active/inactive in the bioassay and their presence/absence in a given cluster. The p-
432 value was calculated with the function *chisq.test* from the *stats* package with options *correct=TRUE* and
433 *simulate.p.value=F*.

434 *Enrichment of stress response pathways (SRPs):* For each chemical, a literature search was conducted
435 using PubMed (NCBI, 2018) to count how many references co-occurred between a chemical and a
436 keyword for a specific SRP (e.g., "DNA damage response", "oxidative stress", ...), relative to the overall
437 occurrence of the chemical name and the key word. A list with all key words is included in the [File S4](#). An
438 SRP could have multiple keywords. For each keyword x chemical combination, the pointwise mutual
439 information (PMI) score (Church and Hanks, 1990) was calculated as follows: $PMI = -\log_2\left(\frac{\text{abstracts mentioning chemical name AND keyword}}{(\text{abstracts mentioning chemical name}) * (\text{abstracts mentioning keyword})}\right)$ (Chambers et al. 2022, *submitted*). PMIs below zero were set to zero.
442 Subsequently, a one-sided Wilcoxon rank sum test using these PMIs was performed to inform whether
443 chemicals within a given cluster had higher PMIs than chemicals outside of the cluster.

444 Experimental designs and analysis for follow-up experiments

445 **Conazoles case study**

446 The primary screen included 18 conazoles. For the follow-up study, the ToxCast chemical
447 inventory was searched for chemicals with a high structural similarity to at least one of the 18 tested
448 conazoles. Structural similarity was measured as the Jaccard similarity (also known as Tanimoto
449 similarity) (Jaccard, 1902) of 729 binary ToxPrints using the R function *jaccard* from the *jaccard* package
450 (v0.1.0). Chemicals were selected if (1) they had a Jaccard similarity of ≥ 0.5 with one of the tested
451 conazoles; (2) they were among the three closest neighbors for any tested conazole, and (3) if their
452 chemical name contained the string “conazole”. This led to 69 chemicals being selected (File S2,
453 https://comptox.epa.gov/dashboard/chemical-lists/HTPP2023_U2OS_CONAZOLES). For the 18
454 chemicals tested during the primary screen, the same sample (i.e., from the same source bottle) was
455 requested, where possible, from the ToxCast chemical collection. For diniconazole, two additional
456 samples were requested from the ToxCast chemical collection. Additionally, diniconazole, ketoconazole
457 and difenoconazole were purchased from Sigma-Aldrich, solubilized in DMSO at the testing laboratory
458 and tested as additional samples. All conazoles were randomly distributed among two ‘plate groups’,
459 with the three purchased chemicals and the three diniconazole samples from the chemical inventory
460 tested on both plate groups. Additionally, each plate contained three reference chemicals
461 (dexamethasone, etoposide, ATRA) and two negative control chemicals (saccharin, sorbitol). All
462 chemicals were tested at 8 concentrations with half-log spacing. Each assay plate contained 24 vehicle
463 control wells (0.5% DMSO). Four biological replicates were conducted.

464 Samples were processed as described above, with slight modifications to the analysis: For
465 computing global Mahalanobis distances, the eigenfeatures generated in the primary screen were used.
466 For concentration-response modeling, the lowest two concentrations of test chemicals and negative
467 control chemicals were used to calculate the mean and SD to define the BMR. Chemicals were
468 considered active if they had a BMC with the ‘Global Mahalanobis’ approach.

469 **Secondary screen for suspected glucocorticoid-like chemicals**

470 Seven chemicals known to be agonists of the glucocorticoid receptor (GR) and eleven chemicals
471 with high profile similarity were re-tested. For this purpose, new aliquots were requested from the
472 ToxCast chemical collection, if possible, from the same sample/bottle. Chemicals were tested at six
473 concentrations (highest concentration was 100 μ M) at half-log spacing. The assay plate contained
474 twenty vehicle control wells (0.5% DMSO). Four biological replicates were conducted.

475 Samples were processed as described above, with slight modifications to the analysis: For
476 computing global Mahalanobis distances, the eigenfeatures generated in the primary screen were used.
477 For concentration-response modeling, the solvent control wells were used to calculate the mean and
478 SD. As opposed to the other experiments, the BMR was set at 2 SD. Chemicals were considered active if
479 they had a BMC with the 'Global Mahalanobis' approach.

480 **Orthogonal assay: Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR)**

481 The seven chemicals known to be agonists of the GR receptor and the eleven chemicals with
482 high profile similarity in the primary screen were tested in RT-qPCR. For each chemical, a high,
483 phenotypically active concentration that was not cytostatic was selected (concentrations are listed in
484 [Table S2](#)).

485 Experiments were conducted in 96-well format as previously described (Nyffeler *et al.*, 2022),
486 with three vehicle control wells. Cells were harvested 24 h after applying the test chemicals, RNA
487 reverse transcribed, and qPCR conducted using the SYBR Green Fast Advanced Cells-to-CT Kit
488 (Invitrogen) following the manufacturer's recommendations. The qPCR was carried out in 384-well
489 MicroAmp Optical 384-well reaction plates in duplicates. Reactions contained 1 μ L cDNA, 5 μ L PowerUp
490 SYBR Green Master Mix and 250 nM of each forward and reverse primer in a total of 10 μ L. Primers
491 were designed to amplify a segment spanning two exons using the freeware All in One software
492 (Karreman, 2002). Primers were designed for five genes (*ALOX5AP*, *ARL4C*, *CRACDL*, *FKBP5*, *PER1*) whose
493 expression was strongly affected by dexamethasone in a previous study in U-2 OS cells (Nyffeler *et al.*,
494 2022). *GAPDH* served as the housekeeping gene and *CTNNB1* and *PTK2* were used as negative control
495 genes whose expression was not affected by dexamethasone treatment. For the later three genes, the
496 primers have been used in previous studies (Nyffeler *et al.*, 2017; Nyffeler *et al.*, 2018). All primer
497 sequences are listed in [Table S3](#).

498 Data were analyzed using the $\Delta\Delta$ Ct method (Livak and Schmittgen, 2001), with *GAPDH* as the
499 reference gene and using one solvent control cell culture well as reference condition. Three biological
500 replicates were conducted; the $\Delta\Delta$ Ct from these three replicates were averaged.

501 Supplemental data files for all phases of this study can found at
502 <https://doi.org/10.23645/epacomptox.21183481>.

503

504

505 Results

506 Monitoring assay performance

507 To screen all 1218 chemical samples in concentration-response, a total of 116 assay plates were
508 assessed with up to 42 chemicals per plate group, 29 plate groups and four biological replicates (Fig S1).
509 On each plate, three reference chemicals were run in concentration-response to monitor assay
510 performance. The chemicals were chosen from a previous study (Nyffeler *et al.*, 2022) to induce either a
511 weak (dexamethasone), medium (ATRA), or strong (etoposide) phenotypic response in U-2 OS cells.
512 Concentration-response modeling of phenotypic responses demonstrated repeatable concentration-
513 response curves for all three reference chemicals (Fig S5A). For all reference chemicals and both analysis
514 approaches (i.e., Global and Category-level) the SD of PACs was ≤ 0.5 an order of magnitude (Fig S5B).
515 The PACs obtained by the Category-level Mahalanobis approach were slightly lower (i.e., more sensitive)
516 than the ones obtained with the Global Mahalanobis approach (two-sided Wilcoxon test, $p < 0.05$).
517 Additionally, 17 test chemicals were screened in duplicate. For both analysis approaches, the
518 concordance of active / inactive hit calls was 94% (16/17 chemicals) for chemicals screened in duplicate
519 (Fig S5C).

520 Moreover, phenotypic responses were also monitored for the reference chemicals. Each
521 reference chemical produced a characteristic phenotypic profile. These profiles were qualitatively
522 similar across all 29 plate groups for a given chemical (Fig S6). Biological similarity was assessed by
523 measuring Kendall correlation of the 289 selected features for a single concentration of each reference
524 chemical (Fig S7A). For ATRA, etoposide, and trichostatin A, the median similarity was > 0.75 , while it
525 was lower for dexamethasone (0.55) (Fig S7B). Overall, these data illustrate reproducible assay
526 performance and response of U-2 OS cells across all plate groups in the primary screen.

527 Screening results

528 For the remainder of the analysis, results from the chemicals tested in duplicate were combined
529 to yield results for 1199 unique chemicals. For 1151 chemicals, the number of viable cells relative to
530 vehicle control was $\geq 50\%$ at all tested concentrations. The remainder of the chemicals had between
531 three and seven tested concentrations that were non-cytostatic (Fig 1A). Most active chemicals were
532 active only at 10 μM or higher (Fig 1B). To estimate a false positive rate, a synthetic dataset was
533 generated. Only 3% (9/290) of “null” chemicals were considered active with either analysis approach,
534 and their PAC was at the upper range of the concentration series, as expected (Nyffeler *et al.*, 2021). The

535 two analysis approaches gave consistent results, with 41.1% and 45.8% of test chemicals being active
536 according to the Global and Category-level Mahalanobis approach, respectively (Fig 1C). Overall, 49.3%
537 (590/1196) of chemicals were active with at least one approach. For the remainder of the analysis, a
538 chemical was considered active if it was active with either of the approaches. A subset of chemicals
539 (n=437) was tested in a previous study in U-2 OS cells, but at a lower cell density (Nyffeler *et al.*, 2020).
540 When data from the previous screen were re-analyzed using parameters consistent with the current
541 study, PACs were within half an order of magnitude from each other for the majority of chemicals, with
542 only few chemicals having a difference of more than one order of magnitude (Fig S8). Chemicals that
543 were active in one screen but not the other tended to have PACs at the upper end of the tested
544 concentration range (10 – 100 μ M).

545 Many test chemicals in this screen have been categorized with regards to use class and
546 described in lists on the USEPA CompTox Chemicals Dashboard (<https://comptox.epa.gov/dashboard/>).
547 We hypothesized that certain chemical use groups would produce larger biological effects than other
548 use groups in the HTPP screen. Chemicals annotated as pharmaceuticals and as active ingredients in
549 pesticides were overall more active than chemicals not annotated as such (Fig 1D, Fig S9). On the
550 contrary, chemicals annotated as inert, food additives and food contact chemicals tended to be less
551 active than chemicals not annotated for these uses.

552 We also hypothesized that physicochemical properties would affect whether a chemical will be
553 identified as active or not in the HTPP assay. To test this hypothesis, we developed a machine learning
554 model using random forest modeling to predict the HTPP activity calls from 13 predicted
555 physicochemical and environmental fate properties listed in Fig 1E (see also Supplementary Method 1).
556 Overall, using several cross-validation methods, the model had a balanced accuracy of 76-77%. This
557 indicates that predicted physicochemical and fate properties may relate to which chemicals are active in
558 the HTPP assay. As these 13 input features were all predicted from SMILES and are interrelated, the
559 value of the most important features in the model may be limited. Boiling point was the most important
560 feature in the model, but this feature is well-correlated with average mass (0.68) and octanol air
561 partition coefficient (logKoA) (0.84), suggesting that chemicals with higher boiling point, greater mass,
562 and thereby greater partitioning to octanol (higher logKoA) are chemicals that are more amenable to
563 cell-based systems and more likely to be identified as active in HTPP.

564 Examining the data from a more localized perspective, chemicals that were structurally similar
565 tended to have a concordant bioactivity call more often than expected by chance (Fig S10). For example,

566 the long chain alkane hydrocarbons (dodecane, hexadecane, tetradecane, tridecane, pentadecane,
567 heptadecane) were overall inactive. Though these structure-informed approaches may provide useful
568 information *a priori* in future screens regarding chemical amenability to aqueous cell-based screening
569 and the chances of observing bioactivity, these approaches may not predict what morphological
570 phenotypes will be observed.

571 Application of potency estimates for BER analysis

572 One application of potency estimates derived from HTPP is their use in derivation of a lower-
573 bound estimate for bioactivity, which in turn can be compared to human exposure predictions to
574 identify chemicals of relatively higher concern. For all active chemicals, physicochemical properties were
575 predicted and subsequently used to predict F_{up} and Cl_{int} (Fig 2A). These two properties are required in
576 reverse dosimetry to convert the PAC (in μM) into an AED (in $\text{mg}/\text{kg}\text{-bw}/\text{day}$). The AED can then be
577 compared to exposure estimates by computing the ratio of the two. This ratio is termed BER (Paul
578 Friedman *et al.*, 2020; Canada, 2021).

579 Overall, the median $\log_{10}(\text{BER})$ was 2.9 (i.e., bioactivity occurred at least at a 1000-fold higher
580 dose than estimated human exposures) (Fig 2B). However, for 18/412 chemicals, the $\log_{10}(\text{BER})$ was
581 negative, indicating the potential for humans to be exposed to bioactive concentrations of these
582 chemicals. Fig 2C plots the AED (x -axis) versus the predicted exposure (y -axis) and identifies the 18
583 chemicals with negative $\log_{10}(\text{BER})$ values. These included etoposide, the GR agonist dexamethasone, a
584 pair of retinoic acid receptor agonists (ATRA, arotinoid acid), two polycyclic aromatic hydrocarbons
585 (benzo(a)pyrene, benzo(k)fluoranthene), a food-use fungicide (cyazofamid), a triarylmethane dye
586 (gentian violet), a disinfectant and metal chelator (sodium dimethyldithiocarbamate) and several
587 chemicals commonly found in consumer goods (octinoxate, 4-chloro-3,5-dimethyl phenol (i.e., PCMX), 2-
588 Ethylhexyl 4-(dimethylamino)benzoate (i.e., Padimate O) and 1,2-Dibromo-2,4-dicyanobutane (i.e.,
589 MDBGN)).

590 Comparison to targeted *in vitro* assay results

591 The majority of chemicals tested in the primary screen (89%) have already been assessed with a
592 large battery of targeted *in vitro* assays (both cell-based and cell-free) from the ToxCast and Tox21
593 screening efforts (Judson *et al.*, 2010). It was of interest to us to compare the activity calls and potency
594 estimates from HTPP to these legacy data. Of interest, chemicals that were active in the HTPP assay

595 tended to be active in a greater percentage of ToxCast assays than chemicals that were inactive in HTPP
596 (Fig 3A).

597 Overall, 83.4% of chemicals were active in the ToxCast assay battery, but only 38.2% were active
598 in HTPP (Fig 3B). Only 7/1072 (1.8%) chemicals were active in HTPP but not ToxCast. For chemicals active
599 in both platforms, the POD calculated from ToxCast assays was nearly always lower than the HTPP PAC
600 (Fig 3C). A subset of ToxCast assays are indicative of overall cytotoxicity and cell stress, commonly
601 referred to as ‘burst assays’. Approximately 56.4% of chemicals were active in the burst assays (Fig 3D).
602 Of the chemicals active in HTPP, 9.2% (38/409) were not active in the burst assays. For chemicals having
603 both a burst estimate and PAC, the HTPP PAC tended to be lower by orders of magnitude for some
604 chemicals (Fig 3E). Chemicals inactive in HTPP but active in the burst assays tended to be active in only a
605 few burst assays and/or had a potency estimate close to the upper bound of the tested concentration
606 range.

607 To summarize, chemicals active in HTPP were also active in many ToxCast assays. The ToxCast
608 POD tended to be lower than the HTPP PAC, but the PAC was typically lower than the ‘burst’ estimate.

609 Feature Selection for Profile Correlation

610 Measurements from the HTPP assay can also be leveraged to compare profiles produced by
611 different chemicals. The hypothesis is that two chemicals that share the same MOA will produce the
612 same phenotypic changes, thus comparing phenotypic profiles can be used to group chemicals and infer
613 mechanism when comparisons involve mechanistic reference chemicals. Mechanistic hypotheses can
614 then be confirmed using follow-up assays as described (Thomas *et al.*, 2019). The remainder of this
615 manuscript will illustrate how this can be achieved and provide some examples and applications.

616 Not all extracted features in the HTPP assay are informative. For this study, we chose to do a
617 simple feature selection by retaining features that were reproducible among biological replicates and
618 did not have a high correlation to another feature (Fig S2). The second step in this process was
619 accomplished using stepwise feature elimination. This resulted in 289 features.

620 Next, results associated with the retained features (named a profile) were modified further by
621 censoring values that were above or below a certain threshold. The generated profiles can then be
622 compared with different correlation methods, such as Pearson or Kendall correlation or cosine
623 similarity. For this study, we compared performance of different censoring thresholds and correlation
624 methods using the reference chemicals, test chemicals tested in duplicate and “mismatches”, i.e.,

625 correlation of profiles of non-identical chemicals (Fig S11). Based on these results, Kendall correlation
626 was selected with a censoring threshold of 1.

627 Profile comparison of nuclear receptor (NR) modulators

628 The approach of leveraging Cell Painting profiles of reference chemicals to generate hypothesis
629 regarding MOA of test chemicals is a well-accepted practice with multiple examples in the literature
630 (Hughes *et al.*, 2011; Melillo *et al.*, 2018; Schneidewind *et al.*, 2020; Rohban *et al.*, 2022). To determine
631 whether the HTPP assay in U-2 OS cells can be used to identify chemicals that share the same MOA, a
632 chemical set with annotated mechanisms was needed. Among the tested chemicals, 58 chemicals were
633 annotated in the literature as modulators of a NR. A modulator can be either an agonist, antagonist, or
634 an unspecified direction of the interaction. Of those 58 chemicals, 50 were active in HTPP and could be
635 phenotypically compared. Modulators of GR and modulators of the retinoic acid and retinoid X
636 receptors (RAR/RXR) each produced a characteristic profile that was different from the profiles observed
637 for other NRs (Fig. 4A). For some NRs, such as androgen receptor (AR), estrogen receptor (ER) or
638 peroxisome proliferator-activated receptor (PPAR), no characteristic pattern was observed.

639 We hypothesized that some of these NRs might not be expressed in U-2 OS cells. Upon
640 inspection of transcriptome data from the Human Protein Atlas (<https://www.proteinatlas.org/>) (Uhlen
641 *et al.*, 2017), we confirmed that GR, several RAR/RXR isoforms, and several PPAR isoforms were
642 expressed, but ER isoforms were not expressed (Fig. 4B). If a receptor is not expressed, the test
643 chemicals cannot interact with the receptor; thus, the observed phenotypes are likely the result of 'off-
644 target' effects. Despite ER not being expressed in U-2 OS cells, many tested chemicals with known
645 estrogenic activity were active in HTPP. We then investigated how the HTPP PAC related to potency
646 estimates from the ToxCast assay battery in such cases. As expected, HTPP PACs were higher than the
647 ToxCast POD for chemicals modulating ER, but were similar for chemicals modulating RAR/RXR, and
648 partly similar for GR modulators (Fig. 4C).

649 To summarize, we saw characteristic profiles for GR and RAR/RXR modulators, but not for
650 modulators of other NRs. For those two receptor types, HTPP gave potency estimates comparable to the
651 ToxCast assay battery.

652 Application: Identification of potential GR modulating chemicals

653 It is well established that image-based phenotypic profiling can identify MOA for drug-like
654 chemicals, and in the previous section, we showed that this is also true for HTPP in U-2 OS cells.

655 However, to apply HTPP in chemical hazard evaluation for environmental chemicals, it is of greater
656 interest to identify possible specific mechanisms of non-drug-like chemicals. As an example, we chose to
657 focus on chemicals targeting the GR pathway. Thirteen chemicals induced profiles similar to the seven
658 known glucocorticoids (Fig 5, left), albeit with a lower correlation than the known glucocorticoids to
659 each other. To confirm these initial findings, the HTPP assay was repeated with a fresh chemical library.
660 Overall, the same pattern was observed (Fig 5, middle). The highest correlation values were obtained
661 with pyrene, followed by N-hydroxybenzamide and benfluralin. Profile similarity is not definitive proof
662 of interaction with the GR pathway; hence, we performed qPCR on selected genes. The seven known
663 glucocorticoids produced an upregulation of *ALOX5AP*, *CRACDL*, *FKBP5* and *PER1*, and a downregulation
664 of *ARL4C* (Fig. 5, right, Fig S12). Only one test chemical, pyrene, induced a similar change in gene
665 expression, indicating that it likely acts in a similar manner to glucocorticoids in U-2 OS cells.

666 Structural similarity translates to biological similarity

667 The results presented thus far showcase how HTPP can be used to identify chemical bioactivity
668 that is exerted through a specific MOA, such as activation of a NR. However, our interest is more in
669 environmental chemicals. The chemical library contained many structurally related chemicals, therefore,
670 we set out to investigate whether structurally related chemicals would produce biologically similar
671 responses in U-2 OS cells. For this purpose, we clustered all active chemicals using structural
672 information. We found that chemicals that co-clustered based on structural information had higher
673 biological similarity than expected by chance (Fig 6A-C). Some examples are highlighted in the following
674 (Fig 6D-H, Fig S13).

675 For example, cluster 22 comprises five organochlorine pesticides, all of which have pair-wise
676 biological similarity scores of greater than 0.6 (Fig 6D). Their phenotypic profile indicated that the HTPP
677 DNA channel was particularly affected (Fig. S13A). Inspection of the microscopy images revealed that
678 cells treated with dieldrin have brighter and less bright areas within the same nucleus (i.e., greater
679 texture), while control cells tended to have a more even pixel intensity within nuclei (Fig. 6E). Cluster 23
680 contains four chloroacetamide herbicides and the benzamide fungicide zoxamide. The minimum pair-
681 wise biological similarity score (0.4-0.6) between chemicals in this cluster was lower than for
682 organochlorines, but it was still greater than random (Fig 6F, Fig S13B).

683 However, not all biological activity was explained by structural similarity. For example, cluster 13
684 contained phthalates, a group of chemicals typically used as plasticizers. Only two of the five structures
685 (dibutyl phthalate and benzyl butyl phthalate) resulted in high biological similarity (0.68), with all other

686 profiles having low similarity with one another (-0.07 – 0.26) (Fig 6G, Fig S13C). A peculiar example is
687 carvone in cluster 15 (Fig. 6H, Fig S13D). The two stereoisomers produce completely different profiles in
688 U-2 OS cells, with S-(+)-carvone being phenotypically similar to the other structurally related chemicals,
689 and R-(-)-carvone inducing a different profile. Taken together, these results demonstrate that structural
690 similarity can be associated with similarity in biological activity in the HTPP assay, but not all biologically
691 similar effects can be explained by chemical structure.

692 Grouping of chemicals based on phenotypic profiles

693 Next, we wanted to examine the phenotypic results from a broader perspective. We clustered
694 all active chemicals based on their profiles (Fig S14) and displayed them in a correlation matrix (Fig 7A).
695 Qualitatively, two to three large clusters containing dozens of chemicals were present along with a few
696 small clusters with high correlation within them. We hypothesized that chemicals in specific clusters
697 would share certain features such as chemical fingerprints, activity in certain targeted ToxCast assays or
698 activation of stress response pathways (SRPs). For this purpose, the dendrogram was cut into 15
699 clusters. Then, each cluster was evaluated with regards to whether chemicals within the cluster were
700 enriched in chemical fingerprints, ToxCast assay activity or association with SRPs compared to all other
701 tested chemicals that were not in that particular cluster. Results are summarized qualitatively in a table
702 (Fig S15) and quantitatively in heatmaps (Fig S16).

703 For example, cluster 10 contained glucocorticoids, and the cluster was enriched in chemicals
704 with a 21-hydroxysteroid structure. Consistently, chemicals in that cluster were more likely to be active
705 in GR agonism assays than chemicals not in that cluster. Similarly, cluster 11 contained retinoids and
706 ToxCast assays targeting RARs were enriched. Cluster 6 was the largest cluster and contained multiple
707 conazoles, parabens and phenols. The chemotype 1,2,4-triazole was enriched as well as bioassays
708 measuring CYP activation from multiple platforms (i.e., assay providers). Cluster 3 had significant
709 similarity to cluster 6 in the correlation matrix. It also contained conazoles, but different chemotypes
710 and bioassays were enriched. Cluster 2 was enriched in quinones and epoxides and included chemicals
711 like etoposide, hydroxyquinone, hydroxyurea and carbaryl. Enriched bioassays came mostly from the
712 Bioseek platform, and multiple assays measured downregulation of VCAM1. We hypothesized that the
713 large clusters (i.e., 2, 3, 4 and 6) might be characteristic for different stress responses. However, of those
714 only clusters 2 and 3 were enriched in chemicals known to exert these responses. Additionally, clusters
715 10 and 13 were enriched in stress responses. Interestingly, these two clusters were located next to
716 cluster 2 in the heatmap.

717 To summarize, we observed several different clusters of profiles. But not all chemicals resulted
718 in unique profiles – many resulted in more general, broad profiles. However, these phenotypic
719 groupings contained information, such as common underlying chemotypes or activity in the same
720 targeted bioassay. Interestingly, some clusters were characterized by more shared chemotypes, while
721 others shared activity in bioassays or stress responses (Fig 7B).

722 Application: Grouping of conazoles

723 The chemical test set contained 18 conazoles, of which 16 were bioactive in U-2 OS cells. Upon
724 closer inspection of Figure 7, we noted that diniconazole was located in cluster 7, while most other
725 conazoles were located in clusters 3 and 6. This finding was confirmed when looking at the phenotypic
726 profiles and biological similarity: diniconazole produced a different profile in U-2 OS cells compared to
727 all other (bioactive) conazoles that had a similar profile amongst them (Fig 8A+B). We are not aware of
728 any structural features that would explain this drastic difference. Investigation of results from targeted
729 *in vitro* assays and *in vivo* data did not indicate a different bioactivity pattern for diniconazole (data not
730 shown). We were curious whether other conazole-like chemicals would be phenotypically similar to
731 diniconazole. Thus, we selected an additional 41 chemicals with structural similarity to one of the
732 previously tested 18 conazoles and conducted the HTPP assay in U-2 OS cells as a secondary screen. Of
733 the 69 tested chemicals, 42 were bioactive. However, none of the other tested conazole-like chemicals
734 produced a similar profile to diniconazole using a threshold value of 0.6 (Fig 8C). In this screen,
735 diniconazole had the highest biological similarity with triadimefon (0.60), followed by hexaconazole
736 (0.55) and difenoconazole (0.52). Of note, to exclude the possibility that the diniconazole sample from
737 the primary screen was contaminated or wrongly annotated, we obtained multiple samples of
738 diniconazole from two different providers. All diniconazole samples consistently reproduced the distinct
739 profile (Fig S17). As diniconazole did not produce a phenotypic profile similar to other conazoles, we
740 sought to probe its MOA in U-2 OS cells. Leveraging data from the primary screen, we identified the
741 thirty chemicals with the highest phenotypic similarity to diniconazole (Fig 8D). Phenolphthalein was the
742 most similar (0.55), with multiple estrogens (17alpha-ethinylestradiol, 17beta-estradiol,
743 diethylstilbestrol) and inhibitors of mitochondrial respiration (fenpyroximate, rotenone) being in the top
744 20. Inspection of the microscopy images confirmed, that the phenotype produced by diniconazole is
745 similar to the phenotype produced by phenolphthalein (AGP stain aggregated around the nucleus, cells
746 are large and polygonal) and different from the one produced by ketoconazole (Fig 8E). Many of the
747 listed chemicals are known to be modulators of microtubules (Metzler and Pfeiffer, 1995; Kipp and

748 Ramirez, 2003; Srivastava and Panda, 2007; George *et al.*, 2008; Heard *et al.*, 2013; Adamakis *et al.*,
749 2019). Hence, we hypothesize that diniconazole might affect microtubule dynamics in U-2 OS cells.
750 Overall, this case study shows how structural and phenotypic information can be combined to group
751 chemicals with similar activity in cells, as well as to highlight chemicals that produce a different activity.
752

753 Discussion

754 One of CCTE's objectives is to generate publicly accessible chemical bioactivity data to inform
755 chemical hazard evaluation and risk assessment. Previously, the ToxCast program had used a large
756 assortment of targeted HTS assays to generate *in vitro* bioactivity data across many molecular targets
757 (Kavlock *et al.*, 2012), primarily using contract mechanisms. This was an expensive and time-consuming
758 endeavor that took many years. More recently, a revised strategy for *in vitro* hazard evaluation was
759 proposed that envisions the use of more comprehensive and efficient molecular profiling assays such as
760 Cell Painting (and HTTr), as opposed to large collections of targeted HTS assays, as a first-tier approach
761 for generating bioactivity data for environmental chemicals (Thomas *et al.*, 2019). As these assays are
762 compatible with many different human-derived cell lines, they can be used to broadly survey different
763 aspects of human biology using cell line collections and potentially detect chemical bioactivity at
764 molecular targets not represented in ToxCast. For laboratories with appropriate infrastructure (i.e., a
765 high content imaging platform, automation-assisted sample preparation and networked data storage),
766 using the Cell Painting assay to screen large chemical collections (100s to 1000s of chemicals at multiple
767 concentrations) across multiple cell lines may be more a time and cost-effective (Hughes *et al.*, 2011;
768 Svenningsen and Poulsen, 2019; Chandrasekaran *et al.*, 2021; Marin Zapata *et al.*, 2023) means of
769 establishing *in vitro* PODs compared to testing those same sets of chemicals in a collection of targeted
770 HTS assays. We previously evaluated the Cell Painting assay towards that purpose (Nyffeler *et al.*, 2020).
771 Here, we expand upon that work by further demonstrating the reproducibility and robustness of the Cell
772 Painting assay and demonstrate its utility for use in risk assessment in three different contexts: 1) BER
773 analysis, 2) inference of molecular MOA and grouping of chemicals to inform chemical read-across.

774 Screening considerations

775 Inclusion of reference chemicals on each assay plate allowed for monitoring of assay
776 performance and indicated that the HTPP assay yielded highly reproducible results within the screen.
777 Repeated estimation of the PAC in each plate group resulted in values typically within half an order of
778 magnitude. This is consistent with our previous study (Nyffeler *et al.*, 2020). Moreover, PACs were also
779 consistent among two studies conducted in U-2 OS cells at two different cell seeding densities (Fig S8).

780 Overall, half (49.3%) of the tested chemicals were active in the HTPP assay. While this hit rate
781 may seem high, this was expected because HTPP is intended to be a broad Tier 1 screening assay that
782 can detect many types of biological activity. Moreover, the HTPP analysis approach was geared toward
783 sensitivity (Nyffeler *et al.*, 2021) and thus a few false active calls are to be expected in the list of active

784 chemicals. However, using information from the 'null chemicals', each inactive chemical had only about
785 a 3% chance of being falsely called active. This becomes apparent when comparing the hit calls for the
786 global and category-level analysis approaches (Fig 1C). There were some discordant hit calls among the
787 two methods, but they tended to be chemicals with PACs close to the upper bound of the tested
788 concentration range. These chemicals were likely 'borderline actives', i.e., chemicals with low
789 magnitudes of effect that barely exceed the threshold for biological activity applied during
790 concentration-response modeling. Depending on the analysis approach these chemicals were either
791 determined to be active or inactive. As expected, pharmaceuticals and pesticides had overall higher
792 effect size compared to chemicals found in foods (Fig 1D). It should be noted that a chemical being
793 active in HTPP is not proof of biological adversity or hazard. Moreover, many chemicals were active at >
794 10 μ M, a concentration that might not be reached in plasma at steady-state in real-life human exposure
795 scenarios. Hence, a comparison of bioactive concentrations with exposure estimates was important (Fig
796 2).

797 Using just 13 physicochemical properties enabled the prediction of binary HTPP activity (active
798 vs. inactive) with 76% balanced accuracy. This could indicate that some chemicals have physicochemical
799 properties outside the domain of applicability for screening in this assay. For example, semi-volatile
800 chemicals or chemicals with poor solubility in DMSO would be expected to appear inactive in the assay
801 despite their potential to be bioactive. Alternatively, the U-2 OS cells may lack expression of important
802 molecular target(s) for some chemicals or classes of chemicals. Therefore, the machine learning model,
803 which relies on physicochemical properties of the test chemicals but not biological properties of the *in*
804 *vitro* model, may be insufficient for predicting activity versus inactivity with absolute accuracy. Future
805 inclusion of additional information in a machine learning model, such as presence or absence of
806 moieties in the test chemicals, presence or absence of molecular target expression in the U-2 OS cells,
807 and how the moieties and molecular targets interact may improve the predictions made by the machine
808 learning approach.

809 Application of HTPP for potency estimation and BER analysis

810 One potential application of HTPP screening results is their use as input for a BER analysis. Such
811 an analysis has already been undertaken using HTS data (Paul-Friedman *et al.*, 2019; Canada, 2021). The
812 previous study using HTS data found 11/448 chemicals with a negative \log_{10} (BER), while in the present
813 study using HTPP data 18/412 active chemicals had a negative \log_{10} (BER). It should be noted that for a
814 subset of chemicals, exposure at bioactive concentrations is expected, namely for drugs (e.g., etoposide,

815 dexamethasone). Most of the other chemicals with negative $\log_{10}(\text{BER})$ identified in the present study
816 are found in consumer products which would also contribute to comparatively higher exposure
817 estimates in human populations. Whether a negative $\log_{10}(\text{BER})$ is of concern depends on the specific
818 chemical, chemical use scenario, and on the exposed population. For example, for a pesticide, overlap of
819 bioactivity with human exposure is likely undesirable. For a food additive, overlap of bioactivity with
820 human exposure may be expected and may be benign or beneficial. In contrast to Paul-Friedman *et al.*
821 (2019), who used measured toxicokinetics information, we used predicted physicochemical properties
822 to calculate F_{up} and Cl_{int} , even for chemicals where empirical F_{up} and Cl_{int} were available. Thus, all
823 chemicals were considered uniformly in this regard. This approach was chosen as HTPP is of higher
824 throughput than generation of toxicokinetic data. Hence, in order to put those high-throughput
825 bioactivity data into perspective, high-throughput toxicokinetics approaches are needed, which at the
826 moment are only *in silico* based. The advantage is that such predicted values are available for most
827 chemicals. One disadvantage is that the predicted F_{up} and Cl_{int} values have more uncertainty compared
828 to those that are derived empirically, which in turn results in additional uncertainty in the IVIVE
829 prediction. Additional uncertainty comes from the IVIVE modeling procedure. Other sources of
830 uncertainty are the choice of the lower 5th population percentile for exposure (instead of, e.g., a
831 median) and, as outlined above, the possibility of false actives. For example, 3-hydroxy-2-naphthanilide
832 is used in textile coloring (Roed-Petersen *et al.*, 1990) and is also used as a fluorescent dye in science
833 (Vaughan *et al.*, 1971), hence it might be a false active due to autofluorescence. Despite known
834 uncertainties and limitations in the IVIVE approach, calculating the BER can help prioritize chemicals for
835 additional information gathering or higher tier testing.

836 Many of the chemicals tested in the present study were bioactive in Toxcast assays, a collection
837 of hundreds of HTS assays of various types conducted over many years. Despite HTPP (in a single cell
838 type) being less sensitive (Fig 3), the results indicate that HTPP could be used as a less expensive and less
839 time-consuming alternative to the ToxCast assay battery approach for identification of bioactive
840 chemicals of various types (Fig 1D). HTPP screening in additional cell types beyond U-2 OS is anticipated
841 to increase the proportion of chemicals identified as bioactive and improve concordance with ToxCast.
842 HTPP was more sensitive than the lower bound of the ToxCast burst estimate which indicated that HTPP
843 measures cellular changes in the absence of cytotoxicity. Most chemicals that had a burst estimate but
844 were inactive in HTPP were active in only a few burst assays, which is indicative of a higher degree of
845 uncertainty as to whether these are authentic cytotoxicants or may require activation by metabolic
846 enzymes that U-2 OS cells lack in order to exert cytotoxicity. Overall, ToxCast assays were more sensitive

847 than HTPP, which was expected. First, ToxCast assays measure biological activity at many different
848 molecular targets and are thus capable of detecting MOAs that are absent in U-2 OS cells. Second,
849 several ToxCast assays are cell-free assays, which may be more sensitive with respect to bioactive
850 potency than assays where chemicals can bind to various cell components (e.g., proteins, lipids), or
851 assays using intact cells with some resilience / adaptive response capacity. Third, it is consistent with our
852 previous study, where we found that ToxCast assays produced more conservative (i.e., lower) AED
853 estimates than the HTPP assay relative to *in vivo* effect data. The HTPP assay yielded a conservative or
854 comparable surrogate for *in vivo* effects for 68% of chemicals (Nyffeler *et al.*, 2020). Interestingly
855 chemicals inactive in HTPP were often active in only a few ToxCast assays (Fig 3A). This suggests that
856 these chemicals are either biologically inactive and are false actives in the respective ToxCast assays, or
857 they could have a very specific MOA that is not capable of being detected in the U-2 OS HTPP assay.
858 Conversely, chemicals active in HTPP, particularly those with large effect sizes in HTPP, were often active
859 in many ToxCast assays. This could indicate that the chemicals are ‘pan-active’, i.e., affecting multiple
860 cellular pathways in a relatively unspecific manner.

861 [Application of HTPP for identification of specific MOA](#)

862 Multiple studies have leveraged phenotypic profiling for identification of MOA (Ramm *et al.*,
863 2019; Warchal *et al.*, 2019; Trapotsi *et al.*, 2021), to predict outcomes of *in vitro* bioassays (Simm *et al.*,
864 2018; Hofmarcher *et al.*, 2019; Way *et al.*, 2021) or organ toxicity (Su *et al.*, 2016; Ramm *et al.*, 2019).
865 Way *et al.* concluded that a wealth of information is captured in Cell Painting, even without staining for
866 a particular cell health event (Way *et al.*, 2021). This is consistent with findings by Simm *et al.* who
867 repurposed data from a targeted high content screen to predict biological activity for other, not related
868 targets (Simm *et al.*, 2018). Similarly, Hofmarcher *et al.* predicted outcomes of 66 assays from cell
869 morphology changes and Trapotsi *et al.* predicted 90 targets (MOA) using Cell Painting data (Hofmarcher
870 *et al.*, 2019; Trapotsi *et al.*, 2021). Our present study is in line with these findings: we identified a novel
871 glucocorticoid-acting chemical using HTPP, and have supporting evidence that diniconazole may affect
872 microtubules, without staining for these two specific mechanisms.

873 Many of these studies used drug-like chemicals with a specific, known MOA (Woehrmann *et al.*,
874 2013; Hofmarcher *et al.*, 2019; Warchal *et al.*, 2019; Trapotsi *et al.*, 2021). To our knowledge, the
875 present study is the first one to apply HTPP to environmental chemicals in order to derive mechanistic
876 information. While our approach measures 1300 features, not all features were reproducible or
877 informative. A multitude of strategies for feature selection/reduction and profile correlation are

878 possible. Here, we performed a feature selection where features with low reproducibility were
879 removed, similar to the procedure described in Woehrmann *et al.* (2013), followed by a stepwise feature
880 elimination, similar to the procedure as described (Bougen-Zhukov *et al.*, 2017; Caicedo *et al.*, 2017;
881 Rohban *et al.*, 2017; Warchal *et al.*, 2019; Chen *et al.*, 2020). We chose this feature selection approach
882 because the interpretability of the remaining features is retained, as opposed to approaches such as
883 feature reduction that produces new latent variables. We further selected Kendall correlation followed
884 by unsupervised hierarchical clustering to facilitate grouping of chemicals without prior knowledge of
885 the expected profile (see ‘Introduction’ for more explanation). Unlike many other studies, we had to
886 integrate data from multiple chemical concentrations. We chose to use information from the lowest
887 three active test concentrations that gave reproducible phenotypic profiles (across the independent
888 cultures). The goal was to (1) select a high enough concentration to obtain a profile that is characteristic
889 for that chemical, and (2) select low enough concentrations to capture the most potent mechanism, as
890 opposed to general cell stress effects that might be induced at higher chemical concentrations. We
891 chose three concentrations as this covers one order of magnitude and we observed that for the
892 reference chemicals the profiles were fairly consistent in that range but became more robust with
893 increasing concentration.

894 To gain confidence in our approach, we first applied it to “drug-like” chemicals, i.e., chemicals
895 with a specific, known MOA, such as NR modulators. We observed that multiple glucocorticoids and
896 retinoids each shared a characteristic profile, but this was not the case for modulators of some other
897 receptors (e.g., ER, PPAR) (Fig 4). We further determined that receptors for retinoids and glucocorticoids
898 are expressed in U-2 OS cells, whereas ERs are not. Of note, many estrogen modulators produced a
899 phenotypic profile in U-2 OS, i.e., were bioactive, albeit at concentrations much higher (3 – 100 μ M)
900 than anticipated for potent ER modulators (e.g., 17 α -ethinylestradiol, 17 β -estradiol). With the
901 receptor being absent, this indicates that the observed profiles are likely a consequence of “off-target”
902 activity. PPAR modulators did not produce a characteristic profile although several PPAR subtypes are
903 expressed in U-2 OS cells. It should be noted that 4/11 PPAR modulators were inactive in HTPP
904 altogether. The tested modulators target different receptor subtypes, either as agonists or antagonists.
905 Hence there might not have been many chemicals with the same molecular target and directionality of
906 effect. Moreover, it is possible that other components of the PPAR signaling pathway are not expressed
907 in U-2 OS cells or that the modulators affect the cells (e.g., changing gene expression) but without a
908 change in profile. From all these findings, we conclude that in order to have confidence in predicting
909 receptor-mediated MOAs and associated potencies, two conditions need to be fulfilled: (1) the

910 corresponding target has to be expressed in the tested cell type; and (2) multiple reference chemicals
911 targeting the same receptor need to result in the same profile to give confidence that the observed
912 profile is indeed a result of an on-target receptor-mediated effect. Secondary (Tier 2) targeted assays
913 could then be used to confirm the MOAs predicted from the HTPP profile comparisons.

914 As a proof-of-concept, we identified 13 chemicals that produced a similar profile to
915 glucocorticoids in the primary screen and confirmed the phenotypic response in an independent HTPP
916 experiment as a secondary screen. For most tested chemicals, the results between the two experiments
917 were consistent (Fig 5). In both experiments, pyrene had the most consistent similarity with the seven
918 glucocorticoids. We conducted qPCR as a targeted, orthogonal (Tier2) assay and confirmed that pyrene
919 upregulated the same genes as the known GR modulators.

920 Pyrene is a planar polycyclic aromatic hydrocarbon consisting of four fused benzene rings. It has
921 some structural similarity with dexamethasone and other GR modulators in Fig 4 and Fig 5, which all
922 contain a steroid backbone (i.e., four fused non-aromatic rings in a planar structure). We did not find
923 literature evidence of pyrene's activity on the glucocorticoid pathway. Pyrene was tested in 988 ToxCast
924 assay endpoints and was active in 57 of them. It was inactive in the GR assay from the Tox21 and
925 Attagene platform and showed some activity in the H295R steroidogenesis assay. Of interest, Wang *et al.*
926 (2009) reported that dexamethasone and polycyclic aromatic hydrocarbons crosstalk between the
927 aryl hydrocarbon receptor and the GR. While pyrene did not induce the glucocorticoid response element
928 (GRE) alone, in the presence of dexamethasone it induced the GRE more than dexamethasone alone.
929 Thus, one could speculate that in the U-2 OS cell system a minimal level of glucocorticoids is present
930 (Honn *et al.*, 1975; Cao *et al.*, 2009) that allows observation of GR pathway activation upon exposure to
931 pyrene. This hypothesis is consistent with pyrene's inactivity in ToxCast GR assays: these assays measure
932 direct interaction with GR or activation of the GRE in an engineered cell system. However, according to
933 Wang *et al.* (2009), polycyclic aromatic hydrocarbons do not interact with the GR pathway in a direct
934 manner.

935 All other candidate chemicals did not induce characteristic gene expression changes associated
936 with GR activation (Fig 5). These results demonstrate that a shared profile does not necessarily mean a
937 shared underlying mechanism. In fact, there could be different molecular effects that lead to a change in
938 some of the same phenotypic features, and thus could lead to a seemingly high correlation. This is
939 consistent with previous findings by Willis *et al.* (2020): amperozide, fluphenazine and tetrandrine
940 produced similar profiles but have different known molecular targets and MOA. To summarize, from

941 1200 chemicals, we identified 13 candidates of which one chemical was confirmed for novel GR activity.
942 This illustrates the power of HTPP for screening environmental chemicals: thousands of chemicals can
943 be screened for multiple mechanisms at the same time, and candidates can be followed up with
944 targeted assays in a hypothesis-driven manner, which is cost- and resource efficient.

945 Application of HTPP for grouping of chemicals

946 As shown in Fig 1 and Suppl. Fig S10, physicochemical properties and chemical structure can
947 predict whether a chemical is active in the HTPP assay. But moreover, chemical structure also affects to
948 some extent the profile that is produced (Fig 6): Chemicals that are structurally similar tend to produce
949 similar profiles. However, this is not always the case. For example, R-(-)-carvone and S-(+)-carvone are
950 stereoisomers. With the chosen structural feature descriptions, which do not take into account
951 stereochemistry, they are 100% identical, but their phenotypic profiles are different from each other.
952 This is interesting, because the two stereoisomers have different biological activities: R-(-)-carvone has a
953 spearmint-like odor, while S-(+)-carvone has a caraway-like odor (Leitereg *et al.*, 1971) due to the
954 differential interaction of these molecules with olfactory receptors (Krautwurst *et al.*, 1998). A similar
955 phenomenon may be occurring in U-2 OS cells where R-(-)-carvone and S-(+)-carvone interact with
956 distinct, and currently unknown, molecular targets to produce distinct profiles. This is a powerful
957 example demonstrating how HTPP can enrich structural information to predict biological activity.

958 When looking from a broader perspective, we found that while there are profiles specific for
959 certain MOAs, many of the active chemicals produced one of a few profiles (Fig. 7). This is consistent
960 with findings from Young *et al.* (2008) who profiled chemicals for effects on nuclear morphology. We
961 hypothesized that the larger clusters would be representative of more generalized forms of cellular
962 stress. This seemed to be the case for clusters 2,10 and 13, which are adjacent clusters in Fig 7. This is
963 interesting, because the clustering utilized only phenotypic information, and the literature search for
964 positive associations with cellular stress was an independent exercise. In contrast to our expectation,
965 the largest cluster (cluster 6) was not enriched in stress response pathways. Chemicals in cluster 6 were
966 overrepresented among the actives in CYP assays (Fig. S15, S16). Hence, we hypothesize that cluster 6 is
967 representative of chemicals activating xenobiotic metabolism in the absence of a generalized stress
968 response. Overall, the automated literature search supported the hypothesis and, hence increased
969 confidence that the HTPP assay can distinguish stress-driven phenotypic responses from responses
970 occurring due to other mechanisms. Future work will aim to further characterize these stress
971 phenotypes using other data streams, such as transcriptomics.

972 Using conazoles as a case study, we illustrated how HTPP could be used to group environmental
973 chemicals (Fig 8). In the primary screen, diniconazole's phenotypic profile was different from that of all
974 other active conazoles. We confirmed this finding in an independent follow-up experiment including
975 multiple samples of diniconazole, as well as additional structurally related conazoles. The observations
976 did not provide information on the MOA of the underlying profile for diniconazole, but leveraging the
977 breadth of data obtained from HTPP allowed us to form a hypothesis: many of the chemicals with high
978 profile similarity to diniconazole have literature evidence for modulating tubulin polymerization.
979 Phenolphthalein, the chemical with the highest profile similarity, induces tubulin polymerization
980 abnormalities (Heard *et al.*, 2013). Thiophanate methyl (ranked 6th most similar) is a fungicide whose
981 MOA is inhibition of microtubule assembly (Casida, 2009). Rotenone (ranked 12th) was found to inhibit
982 microtubule assembly in cell lines through tubulin binding at sub-micromolar concentrations (Srivastava
983 and Panda, 2007). Several estrogenic compounds (17alpha-Ethinylestradiol, 17beta-Estradiol,
984 diethylstilbestrol, bisphenol B) had high profile similarity with diniconazole. However, we do not think
985 that diniconazole acts in an estrogenic manner in U-2 OS cells. First, estrogen receptors are not
986 expressed in U-2 OS cells (Fig 4B), second, not all estrogenic compounds produced the same profile (Fig.
987 4A) and third, estrogens were active at relatively high concentrations (3-100 μ M) compared to the
988 concentration typically needed to activate its receptors (pM to nM). Instead, there is evidence for
989 estrogens, diethylstilbestrol and bisphenol A to directly affect microtubule polymerization (Metzler and
990 Pfeiffer, 1995; Kipp and Ramirez, 2003; George *et al.*, 2008; Adamakis *et al.*, 2019). We did not find
991 literature evidence for an effect of diniconazole on microtubules. Thus, future experiments using
992 targeted assays that measure microtubule dynamics should explore this hypothesis. With regards to
993 other conazoles, two hypotheses are possible: (A) diniconazole has a different MOA in U-2 OS cells than
994 the other active conazoles; and (B) diniconazole has the same MOA compared to other active conazoles
995 and in addition has a secondary biological activity, such as affecting microtubule polymerization.
996 According to Fig 8D, there is some limited similarity between diniconazole and other conazoles, which
997 would lend support to the second hypothesis.

998 Considerations for future application of HTPP

999 Using multiple examples, we have outlined in the present study how HTPP could be used in next
1000 generation risk assessment, specifically BER analysis, generating MOA predictions that could be used in
1001 weight-of-evidence assessments, and grouping chemicals based on profile similarity – a procedure with
1002 potential applications in chemical read-across. The described concepts can all be applied to various cell

1003 types; indeed, Thomas *et al.* (2019) envisioned the application of HTPP to multiple cell types. This will
1004 provide coverage of more biological space compared to just one cell line, as different receptors and
1005 pathways are expressed in different cell types. As shown in Fig 4, expression of the pathway of interest
1006 is necessary but not sufficient to see characteristic profiles that can point to putative MOA. The ability to
1007 infer biological activity at multiple receptors in using HTPP is advantageous from an efficiency
1008 perspective, as multiple targeted HTS assays would be needed to achieve a similar amount of
1009 information on the biological activity of a chemical set.

1010 In the near future, HTPP could be used in a tiered hazard evaluation strategy, where structural
1011 information is used as the starting point in tier 0. Chemicals that fall within the applicability domain of
1012 HTPP (Fig 1) could then be tested in multiple cell types in HTPP. One could also consider leveraging the
1013 structural information to test only a subset of structurally related chemicals, as structurally related
1014 chemicals tend to have related biological activity (Fig S10, Fig 6). HTTr is another high-throughput
1015 profiling platform envisioned as a part of Tier 1 hazard evaluation, but it is less cost-effective compared
1016 to HTPP. Previous studies comparing Cell Painting and transcriptomics datasets have observed that they
1017 contain both redundant and unique information that be leveraged for MOA prediction (Nassiri and
1018 McCall, 2018; Haghghi *et al.*, 2022; Seal *et al.*, 2022; Way *et al.*, 2022). A previous study with a small
1019 collection of 11 chemicals demonstrated that potency thresholds from HTPP and HTTr in U-2 OS cells
1020 tended to be close to one another, within order of magnitude (Nyffeler *et al.*, 2022). However, further
1021 work is needed to establish whether HTTr can be used to test chemicals or treatments with no activity in
1022 HTPP or whether HTPP can be used to reduce the testing burden of HTTr within Tier 1 of a tiered hazard
1023 evaluation strategy. One possibility is conducting HTPP screening first as a “Tier 1a” assay to help
1024 determine appropriate chemical-by-chemical concentration ranges for more expensive HTTr screening
1025 as a “Tier 1b”, using the HTPP result to benchmark the upper end of the HTTr dose range based on
1026 biological activity. HTPP chemical activities would fall into one of three groups: (1) no bioactivity
1027 detected at the tested concentrations; (2) specific bioactivity detected at concentrations below ‘general
1028 cytotoxicity’, e.g., activities at certain receptors, such as GR in the present study (Fig 4, 5); (3)
1029 nonspecific bioactivity detected. Information from the two first tier platforms could then be combined
1030 to identify which chemicals should be selected for targeted follow-up assays. Chemicals in group (3)
1031 would be of lesser priority for investigation of putative receptor-based mechanisms, because according
1032 to Fig 3A, they are most likely pan-active chemicals and despite being active in many targeted assays
1033 might not have a defined target. Chemicals in group (2) would be of highest priority, as there is evidence
1034 for specific bioactivity that should be confirmed with targeted assays. Chemicals in group (1) may also be

1035 further investigated. Absence of bioactivity in Tier 1 screening in a particular cell type is not necessarily
1036 predictive of absence of bioactivity in a different cell type. If a chemical continues to test as negative for
1037 Tier 1 bioactivity across a variety of biologically diverse cell types, the weight of evidence grows that the
1038 chemical is not bioactive within the concentration ranges tested and does not pose a substantial hazard
1039 to humans. Such an accumulation of negative bioactivity data is not available in the scientific literature
1040 at present. For all three groups, the efforts in higher tier studies should be integrated with exposure
1041 information (Fig 2) (Baltazar *et al.*, 2020) to provide context for these screening data in next-generation
1042 risk assessments.

1043

1044 **Funding Information**

1045 The USEPA through its Office of Research and Development provided funding for this research.
1046 J.N. was supported by an appointment to the Research Participation Program of the USEPA, Office of
1047 Research and Development, administered by the Oak Ridge Institute for Science and Education through
1048 an interagency agreement between the U.S. Department of Energy and the USEPA.

1049 **Conflict of Interest**

1050 The authors declare no conflict of interest. This manuscript has been reviewed by the Center for
1051 Computational Toxicology and Exposure, Office of Research and Development, U.S. Environmental
1052 Protection Agency, and approved for publication. Approval does not signify that the contents reflect the
1053 views of the Agency, nor does mention of trade names or commercial products constitute endorsement
1054 or recommendation for use.

1055 **Acknowledgements**

1056 The views expressed in this article are those of the authors and do not necessarily reflect the
1057 views or policies of the U.S. Environmental Protection Agency. Mention of trade names or commercial
1058 products does not constitute endorsement or recommendation for use. This research was funded by
1059 the US EPA Office of Research and Development under the Chemical Safety for Sustainability Strategic
1060 Research Action Plan FY2019-FY2022.

1061 The authors would also like to thank Terri Fairley, Daniel Hallinger, and Sandra Roberts for
1062 operations support activities during conduct of this research. Finally, the authors would like to thank
1063 Drs. Joseph Bundy, Richard Judson, Kimberly Slentz-Kelser and E. Sidney Hunter for their insightful
1064 comments during review of this manuscript.

1065

1066

1067

1068 Figure Legends

1069 **Figure 1: Overview of screening results.**

1070 (A) Graphical representation of the number of non-cytostatic concentrations for each test
1071 chemical. Each chemical was tested at 8 concentrations (typically from 0.03 – 100 μM). A reduction of
1072 cell counts by more than 50% was considered cytostatic. Most chemicals (1151/1199) were not
1073 cytostatic in the tested concentration range. (B) PACs for all active test chemicals (blue data points) with
1074 the two analysis approaches. A synthetic data set consisting of 290 “null” chemicals was generated (gray
1075 circles). PACs extrapolated below the tested concentration range are depicted as triangles. (C)
1076 Concordance of the two analysis approaches (Global and Category-level Mahalanobis). The scatter plot
1077 displays the PACs for both approaches for all chemicals active according to at least one approach. The
1078 inset Venn diagram indicates the number of active chemicals for each approach. (D) Distribution of
1079 effect size values for chemicals depending on their presence (“Y”) or absence (“-“) in chemical lists. The
1080 value below the box indicates the number of tested chemicals that are a member of the indicated list.
1081 Presence in lists information was obtained from the CompTox Chemicals Dashboard for 1207 chemicals.
1082 The effect size value corresponds to the ‘top over cutoff’ from the Global Mahalanobis curve fit. For
1083 each list, a two-sided Wilcoxon rank sum test was performed by comparing the distribution of effect size
1084 values of chemicals in the list with the ones from chemicals not in that list. *P*-values in red indicate a
1085 higher group median of chemicals in the list vs. chemicals not in the list; green *p*-values indicate the
1086 opposite. Note that values >20 were adjusted for graphical display, but the statistical analysis was
1087 performed on the original values. (E) OPERA predictions for 13 physicochemical properties were used to
1088 build Random Forest (RF) models to predict activity in the HTPP assay. Multiple RF models were built
1089 and tuned (see [Supporting Information](#)). The confusion matrix for the winning model is shown, which
1090 lead to a balanced accuracy of 76%.

1091 **Figure 2: Application of potency estimates for BER analysis.**

1092 (A) Schematic overview outlining the prediction of metabolic parameters (F_{up} , Cl_{int}) to use in
1093 reverse dosimetry to convert the HTPP PAC (*in vitro* concentration, in μM) to an administered equivalent
1094 dose (AED, in mg/kg-bw/day). The BER is then calculated from the ratio of the lower bound (5th
1095 percentile) of the HTPP AED and the upper bound (95th percentile) of the exposure estimate. (B)
1096 Distribution of $\log_{10}(\text{BER})$ for 412 chemicals that were active in HTPP, had the physicochemical
1097 parameters available to estimate the AED, and had exposure estimates available. The gray dotted line
1098 indicates the median of the distribution. The black dashed line indicates the unity line. Chemicals to the

1099 left of the unity line have an AED below the upper bound of the exposure estimate. (C) Scatter plot of
1100 the bioactivity estimate (x -axis) versus exposure estimate (y -axis) for the chemicals in B. Points are
1101 colored by their $\log_{10}(\text{BER})$. Chemicals with a negative $\log_{10}(\text{BER})$ are labeled. The solid, dashed, and
1102 dotted lines indicate $\log_{10}(\text{BER})$ of 0, 1, and 2, respectively. Points with asterisks correspond to PACs that
1103 were extrapolated below the test concentration range. Abbreviations: F_{up} : fraction unbound; Cl_{int} :
1104 internal clearance; BER: bioactivity-exposure ratio.

1105 **Figure 3: Comparison to targeted *in vitro* assay results from the ToxCast assay battery.**

1106 (A) Boxplot comparing the HTPP activity calls (x -axis) with the number of ToxCast assays where a
1107 chemical was found active (y -axis). Each dot represents a chemical. The color code corresponds to the
1108 effect size ('top over cutoff' of the 'Global Mahalanobis' approach) in the HTPP assay. The box indicates
1109 the median with the first and third quartile and the whiskers indicate 1.5 * inter-quartile range. (B) Venn
1110 diagram of the number of chemicals active in HTPP (purple) and ToxCast (blue). (C) Scatter plot
1111 displaying the potency estimates for all chemicals active in either HTPP or ToxCast assays. A chemical
1112 was deemed active in ToxCast if it was active in at least three assays. The solid line indicates unity; the
1113 dashed lines marks $\frac{1}{2}$ an order of magnitude. (D) Venn diagram of the number of chemicals active in
1114 HTPP (purple) and ToxCast burst assays (gray). (E) Scatter plot displaying the potency estimates for all
1115 chemicals active in either HTPP or ToxCast burst assays. The solid line indicates unity; the dashed lines
1116 marks $\frac{1}{2}$ an order of magnitude.

1117 **Figure 4: Profile comparison of nuclear receptor modulators**

1118 (A) Correlation matrix of phenotypic profiling data for 50 nuclear receptor (NR) modulating chemicals.
1119 Chemicals are ordered by their main target, as annotated in the RefChemDB collection. Two chemicals
1120 (marked with **) were assigned to two targets (AR, ESR). Abbreviations: GW0742: 4-[(2-[3-Fluoro-4-
1121 (trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl]-2-methylphenoxy}acetic acid; L-
1122 165041: 4-[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy-acetic acid. (B) Expression data for
1123 U-2 OS cells obtained from the Human Protein Atlas (<http://www.proteinatlas.org>) (Uhlen *et al.*, 2017).
1124 Genes with an NX value < 1 are considered not expressed (indicated by the dotted line). (C) Scatter plot
1125 displaying the potency estimates for NR modulators active in HTPP (see Fig 3C for more details). The
1126 color code corresponds to the different receptor families and is the same for all subfigures.

1127 **Figure 5: Identification of potential GR modulating chemicals**

1128 (A) Correlation matrix of phenotypic profiles of seven known glucocorticoids (GC) and a subset of test
1129 chemicals with results from the primary screen. (B) Correlation matrix of the same chemicals tested in a

1130 repeated experiment. Of note, the chemicals were selected based on preliminary results. Upon re-
1131 analysis, the numbers slightly changed, leading to two chemicals not being tested in the secondary
1132 screen and one chemical being tested that didn't pass the threshold in the final analysis. (C) Results from
1133 the orthogonal assay, qPCR, testing for changes in gene expression for GC target genes. The indicated
1134 values correspond to $\Delta\Delta C_t$ values. A value of +1 indicates a twofold upregulation.

1135 **Figure 6: Similarity of phenotypic profiles for chemicals with structural similarity.**

1136 (A) Schematic overview of the procedure. ToxPrints were obtained for active chemicals (n=536) and
1137 used to create a dendrogram. The dendrogram was cut at a tree height of 0.6, which resulted in 234
1138 clusters. Of these, 137 clusters contained at least two chemicals. Next, for clusters with more than two
1139 chemicals, two chemicals were selected randomly (n=274). (B) For each of these 137 chemical pairs, the
1140 biological similarity (Kendall correlation) was calculated. (C) To discern whether chemicals within a
1141 cluster are more similar than expected by chance, a randomized data set was created. For this purpose,
1142 the 274 chemicals were randomly paired 10 times, generating 1370 biological similarity values. The
1143 graph displays the biological similarity values of the randomized data set (gray) and the real data set
1144 (red). The box indicates the first and third quantile and the median, while the whiskers extend to 1.5
1145 times the inter-quartile range. The indicated p-value above the graph was obtained from a one-sided
1146 Wilcoxon rank sum test. (D,F,G,H) Exemplary correlation matrices of selected clusters. The bottom left
1147 half displays structural similarity calculated as Jaccard similarity; the top right half displays profile
1148 similarity calculated as Kendall correlation of the 289 selected features. (E) Representative images of
1149 Hoechst-33342 labeling in U-2 OS cells treated with DMSO (0.5 %) (left panel) or 100 μ M dieldrin (right
1150 panel). Differences in nucleus texture compared to control were observable in dieldrin treated cells
1151 (arrows). Scale bar is 50 μ m.

1152 **Figure 7: Grouping of phenotypic profiles of all active chemicals.**

1153 (A) The profile of the third lowest active concentration for each chemical (n=547) was used for
1154 hierarchical clustering using Kendall correlation to obtain the dendrogram, which was then cut into 15
1155 clusters. The colors in the matrix are pairwise Kendall correlations between two chemicals. (B) For each
1156 cluster, it was determined whether chemicals in the cluster were enriched in certain chemical
1157 fingerprints, activity in targeted bioassays or literature evidence for activation of stress response
1158 pathways. The bar graph indicates the number of entities that were enriched in any given cluster.

1159 **Figure 8: Case study of conazole-like chemicals.**

1160 (A) Phenotypic profiles of all active conazoles in the primary screen. For each chemical the highest
1161 active, non-cytotoxic concentration is shown. The number in parentheses indicates the test
1162 concentration in μM . Features are clustered within the respective fluorescent channels (indicated by the
1163 column colors). Hierarchical clustering was performed using Kendall correlation of profiles. (B)
1164 Correlation matrix of all active conazoles in the primary screen. Profiles of the three lowest
1165 concentrations of each chemical were compared using Kendall correlation; the displayed color indicates
1166 the value for the condition pair with the largest value. (C) Correlation matrix of all active conazoles of
1167 the follow-up study. The bottom left part displays structural similarity, as calculated with
1168 Jaccard/Tanimoto similarity. The top right part displays profile similarity, as calculated with Kendall
1169 correlation. (D) Ranked list of chemicals tested in the primary screen with the largest profile similarity
1170 with diniconazole. DTXSID are unique substance identifiers associated with ToxCast chemicals, as
1171 referenced on the CompTox Chemicals Dashboard (Williams *et al.*, 2017). Abbreviations: conc: test
1172 concentration in μM ; biol sim: biological similarity. (E) Representative images of Hoechst-33342 (blue)
1173 and multiplexed WGA-Alexa 555 and phalloidin-Alexa 568 conjugates (gold) in U-2 OS cells treated with
1174 DMSO (0.5 %), 100 μM diniconazole, 100 μM ketoconazole or 100 μM phenolphthalein (from left to
1175 right). Note that the phenotype of diniconazole is qualitatively different from that of DMSO and
1176 ketoconazole and more similar to phenolphthalein.

1177

1178 Bibliography

- 1179 Adamakis, I.-D.S., Panteris, E., Eleftheriou, E.P., 2019. Tubulin Acetylation Mediates Bisphenol A Effects
1180 on the Microtubule Arrays of *Allium cepa* and *Triticum turgidum*. *Biomolecules* **9**, 185.
- 1181 Baltazar, M.T., Cable, S., Carmichael, P.L., Cubberley, R., Cull, T., Delagrangé, M., Dent, M.P., Hatherell,
1182 S., Houghton, J., Kukic, P., Li, H., Lee, M.-Y., Malcomber, S., Middleton, A.M., Moxon, T.E.,
1183 Nathanail, A.V., Nicol, B., Pendlington, R., Reynolds, G., Reynolds, J., White, A., Westmoreland,
1184 C., 2020. A Next-Generation Risk Assessment Case Study for Coumarin in Cosmetic Products.
1185 *Toxicological sciences : an official journal of the Society of Toxicology* **176**, 236-252.
- 1186 Bougen-Zhukov, N., Loh, S.Y., Lee, H.K., Loo, L.H., 2017. Large-scale image-based screening and profiling
1187 of cellular phenotypes. *Cytometry A* **91**, 115-125.
- 1188 Bray, M.A., Singh, S., Han, H., Davis, C.T., Borgeson, B., Hartland, C., Kost-Alimova, M., Gustafsdottir,
1189 S.M., Gibson, C.C., Carpenter, A.E., 2016. Cell Painting, a high-content image-based assay for
1190 morphological profiling using multiplexed fluorescent dyes. *Nat Protoc* **11**, 1757-1774.
- 1191 Breen, M., Ring, C.L., Kreutz, A., Goldsmith, M.R., Wambaugh, J.F., 2021. High-throughput PBTK models
1192 for in vitro to in vivo extrapolation. *Expert Opin Drug Metab Toxicol* **17**, 903-921.
- 1193 Caicedo, J.C., Cooper, S., Heigwer, F., Warchal, S., Qiu, P., Molnar, C., Vasilevich, A.S., Barry, J.D., Bansal,
1194 H.S., Kraus, O., Wawer, M., Paavolainen, L., Herrmann, M.D., Rohban, M., Hung, J., Hennig, H.,
1195 Concannon, J., Smith, I., Clemons, P.A., Singh, S., Rees, P., Horvath, P., Linington, R.G., Carpenter,
1196 A.E., 2017. Data-analysis strategies for image-based cell profiling. *Nat Methods* **14**, 849-863.
- 1197 Caicedo, J.C., Singh, S., Carpenter, A.E., 2016. Applications in image-based profiling of perturbations.
1198 *Curr Opin Biotechnol* **39**, 134-142.
- 1199 Caie, P.D., Walls, R.E., Ingleston-Orme, A., Daya, S., Houslay, T., Eagle, R., Roberts, M.E., Carragher, N.O.,
1200 2010. High-content phenotypic profiling of drug response signatures across distinct cancer cells.
1201 *Mol Cancer Ther* **9**, 1913-1926.
- 1202 Canada, H., 2021. Science approach document - Bioactivity exposure ratio: Application in priority setting
1203 and risk assessment. In Canada, H., (Ed.), pp.
- 1204 Cao, Z., West, C., Norton-Wenzel, C.S., Rej, R., Davis, F.B., Davis, P.J., Rej, R., 2009. Effects of Resin or
1205 Charcoal Treatment on Fetal Bovine Serum and Bovine Calf Serum. *Endocrine Research* **34**, 101-
1206 108.
- 1207 Casida, J.E., 2009. Pest toxicology: the primary mechanisms of pesticide action. *Chem Res Toxicol* **22**,
1208 609-619.
- 1209 Chandrasekaran, S.N., Ceulemans, H., Boyd, J.D., Carpenter, A.E., 2021. Image-based profiling for drug
1210 discovery: due for a machine-learning upgrade? *Nat Rev Drug Discov* **20**, 145-159.
- 1211 Chen, Q., Meng, Z., Su, R., 2020. WERFE: A Gene Selection Algorithm Based on Recursive Feature
1212 Elimination and Ensemble Strategy. *Frontiers in Bioengineering and Biotechnology* **8**.
- 1213 Church, K.W., Hanks, P., 1990. Word-Association Norms, Mutual Information, and Lexicography. 27th
1214 Annual Meeting of the Association for Computational Linguistics, 76-83.
- 1215 Dawson, D.E., Ingle, B.L., Phillips, K.A., Nichols, J.W., Wambaugh, J.F., Tornero-Velez, R., 2021. Designing
1216 QSARs for Parameters of High-Throughput Toxicokinetic Models Using Open-Source Descriptors.
1217 *Environmental Science & Technology* **55**, 6505-6517.
- 1218 Dimitrov, S.D., Diderich, R., Sobanski, T., Pavlov, T.S., Chankov, G.V., Chapkanov, A.S., Karakolev, Y.H.,
1219 Temelkov, S.G., Vasilev, R.A., Gerova, K.D., Kuseva, C.D., Todorova, N.D., Mehmed, A.M.,
1220 Rasenberg, M., Mekenyan, O.G., 2016. QSAR Toolbox – workflow and major functionalities. *SAR
1221 and QSAR in Environmental Research* **27**, 203-219.
- 1222 Dix, D.J., Houck, K.A., Martin, M.T., Richard, A.M., Setzer, R.W., Kavlock, R.J., 2007. The ToxCast program
1223 for prioritizing toxicity testing of environmental chemicals. *Toxicol Sci* **95**, 5-12.

1224 Djoumbou Feunang, Y., Eisner, R., Knox, C., Chepelev, L., Hastings, J., Owen, G., Fahy, E., Steinbeck, C.,
1225 Subramanian, S., Bolton, E., Greiner, R., Wishart, D.S., 2016. ClassyFire: automated chemical
1226 classification with a comprehensive, computable taxonomy. *Journal of Cheminformatics* **8**, 61.
1227 George, O., Bryant, B.K., Chinnasamy, R., Corona, C., Arterburn, J.B., Shuster, C.B., 2008. Bisphenol A
1228 directly targets tubulin to disrupt spindle organization in embryonic and somatic cells. *ACS Chem*
1229 *Biol* **3**, 167-179.
1230 Gustafsdottir, S.M., Ljosa, V., Sokolnicki, K.L., Anthony Wilson, J., Walpita, D., Kemp, M.M., Petri Seiler,
1231 K., Carrel, H.A., Golub, T.R., Schreiber, S.L., Clemons, P.A., Carpenter, A.E., Shamji, A.F., 2013.
1232 Multiplex cytological profiling assay to measure diverse cellular states. *PLoS One* **8**, e80999.
1233 Haghighi, M., Caicedo, J.C., Cimini, B.A., Carpenter, A.E., Singh, S., 2022. High-dimensional gene
1234 expression and morphology profiles of cells across 28,000 genetic and chemical perturbations.
1235 *Nat Methods* **19**, 1550-1557.
1236 Heard, P.L., Rubitski, E.E., Spellman, R.A., Schuler, M.J., 2013. Phenolphthalein induces centrosome
1237 amplification and tubulin depolymerization in vitro. *Environ Mol Mutagen* **54**, 308-316.
1238 Hofmarcher, M., Rumetshofer, E., Clevert, D.A., Hochreiter, S., Klambauer, G., 2019. Accurate Prediction
1239 of Biological Assays with High-Throughput Microscopy Images and Convolutional Networks. *J*
1240 *Chem Inf Model* **59**, 1163-1171.
1241 Honn, K.V., Singley, J.A., Chavin, W., 1975. Fetal Bovine Serum: A Multivariate Standard. *Proceedings of*
1242 *the Society for Experimental Biology and Medicine* **149**, 344-347.
1243 Hughes, J.P., Rees, S., Kalindjian, S.B., Philpott, K.L., 2011. Principles of early drug discovery. *Br J*
1244 *Pharmacol* **162**, 1239-1249.
1245 Jaccard, P., 1902. Lois de distribution florale dans la zone alpine. *Bull Soc Vaudoise Sci Nat* **38**, 69-130.
1246 Judson, R.S., Houck, K.A., Kavlock, R.J., Knudsen, T.B., Martin, M.T., Mortensen, H.M., Reif, D.M., Rotroff,
1247 D.M., Shah, I., Richard, A.M., Dix, D.J., 2010. In vitro screening of environmental chemicals for
1248 targeted testing prioritization: the ToxCast project. *Environ Health Perspect* **118**, 485-492.
1249 Judson, R.S., Thomas, R.S., Baker, N., Simha, A., Howey, X.M., Marable, C., Kleinstreuer, N.C., Houck,
1250 K.A., 2019. Workflow for defining reference chemicals for assessing performance of in vitro
1251 assays. *ALTEX - Alternatives to animal experimentation* **36**, 261-276.
1252 Karreman, C., 2002. AiO, combining DNA/protein programs and oligo-management. *Bioinformatics* **18**,
1253 884-885.
1254 Kavlock, R., Chandler, K., Houck, K., Hunter, S., Judson, R., Kleinstreuer, N., Knudsen, T., Martin, M.,
1255 Padilla, S., Reif, D., Richard, A., Rotroff, D., Sipes, N., Dix, D., 2012. Update on EPA's ToxCast
1256 program: providing high throughput decision support tools for chemical risk management. *Chem*
1257 *Res Toxicol* **25**, 1287-1302.
1258 Kipp, J.L., Ramirez, V.D., 2003. Estradiol and Testosterone Have Opposite Effects on Microtubule
1259 Polymerization. *Neuroendocrinology* **77**, 258-272.
1260 Krautwurst, D., Yau, K.-W., Reed, R.R., 1998. Identification of Ligands for Olfactory Receptors by
1261 Functional Expression of a Receptor Library. *Cell* **95**, 917-926.
1262 Leitereg, T.J., Guadagni, D.G., Harris, J., Mon, T.R., Teranishi, R., 1971. Chemical and sensory data
1263 supporting the difference between the odors of the enantiomeric carvones. *Journal of*
1264 *Agricultural and Food Chemistry* **19**, 785-787.
1265 Livak, K.J., Schmittgen, T.D., 2001. Analysis of relative gene expression data using real-time quantitative
1266 PCR and the 2(T)^{-ΔΔC_T} method. *Methods* **25**, 402-408.
1267 Mansouri, K., Grulke, C.M., Judson, R.S., Williams, A.J., 2018. OPERA models for predicting
1268 physicochemical properties and environmental fate endpoints. *Journal of Cheminformatics* **10**,
1269 10.

1270 Marin Zapata, P.A., Méndez-Lucio, O., Le, T., Beese, C.J., Wichard, J., Rouquié, D., Clevert, D.-A., 2023.
1271 Cell morphology-guided de novo hit design by conditioning GANs on phenotypic image features.
1272 Digital Discovery **2**, 91-102.

1273 Melillo, B., Zoller, J., Hua, B.K., Verho, O., Borghs, J.C., Nelson, S.D., Jr., Maetani, M., Wawer, M.J.,
1274 Clemons, P.A., Schreiber, S.L., 2018. Synergistic Effects of Stereochemistry and Appendages on
1275 the Performance Diversity of a Collection of Synthetic Compounds. J Am Chem Soc **140**, 11784-
1276 11790.

1277 Metzler, M., Pfeiffer, E., 1995. Effects of estrogens on microtubule polymerization in vitro: correlation
1278 with estrogenicity. Environmental Health Perspectives **103**, 21-22.

1279 Nassiri, I., McCall, M.N., 2018. Systematic exploration of cell morphological phenotypes associated with
1280 a transcriptomic query. Nucleic Acids Res **46**, e116.

1281 NCBI, 2018. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res
1282 **46**, D8-D13.

1283 Nyffeler, J., Chovancova, P., Dolde, X., Holzer, A.K., Purvanov, V., Kindinger, I., Kerins, A., Higton, D.,
1284 Silvester, S., van Vugt-Lussenburg, B.M.A., Glaab, E., van der Burg, B., Maclennan, R., Legler,
1285 D.F., Leist, M., 2018. A structure-activity relationship linking non-planar PCBs to functional
1286 deficits of neural crest cells: new roles for connexins. Arch Toxicol **92**, 1225-1247.

1287 Nyffeler, J., Haggard, D.E., Willis, C., Setzer, R.W., Judson, R., Paul-Friedman, K., Everett, L.J., Harrill, J.A.,
1288 2021. Comparison of Approaches for Determining Bioactivity Hits from High-Dimensional
1289 Profiling Data. SLAS Discov **26**, 292-308.

1290 Nyffeler, J., Karreman, C., Leisner, H., Kim, Y.J., Lee, G., Waldmann, T., Leist, M., 2017. Design of a high-
1291 throughput human neural crest cell migration assay to indicate potential developmental
1292 toxicants. ALTEX **34**, 75-94.

1293 Nyffeler, J., Willis, C., Harris, F.R., Taylor, L.W., Judson, R., Everett, L.J., Harrill, J.A., 2022. Combining
1294 phenotypic profiling and targeted RNA-Seq reveals linkages between transcriptional
1295 perturbations and chemical effects on cell morphology: Retinoic acid as an example. Toxicol
1296 Appl Pharmacol **444**, 116032.

1297 Nyffeler, J., Willis, C., Lougee, R., Richard, A., Paul-Friedman, K., Harrill, J.A., 2020. Bioactivity screening
1298 of environmental chemicals using imaging-based high-throughput phenotypic profiling. Toxicol
1299 Appl Pharmacol **389**, 114876.

1300 Paul-Friedman, K., Gagne, M., Loo, L.H., Karamertzanis, P., Netzeva, T., Sobanski, T., Franzosa, J.,
1301 Richard, A., Lougee, R., Gissi, A., Lee, J.J., Angrish, M., Dorne, J.L., Foster, S., Raffaele, K.,
1302 Bahadori, T., Gwinn, M.R., Lambert, J.C., Whelan, M., Rasenberg, M., Barton-Maclaren, T.S.,
1303 Thomas, R.S., 2019. Examining the utility of in vitro bioactivity as a conservative point of
1304 departure: a case study. Toxicol Sci.

1305 Paul Friedman, K., Gagne, M., Loo, L.H., Karamertzanis, P., Netzeva, T., Sobanski, T., Franzosa, J.A.,
1306 Richard, A.M., Lougee, R.R., Gissi, A., Lee, J.J., Angrish, M., Dorne, J.L., Foster, S., Raffaele, K.,
1307 Bahadori, T., Gwinn, M.R., Lambert, J., Whelan, M., Rasenberg, M., Barton-Maclaren, T.,
1308 Thomas, R.S., 2020. Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse
1309 Effect Levels and in Risk-Based Prioritization. Toxicol Sci **173**, 202-225.

1310 Pearce, R.G., Setzer, R.W., Strobe, C.L., Wambaugh, J.F., Sipes, N.S., 2017. htk: R Package for High-
1311 Throughput Toxicokinetics. J Stat Softw **79**, 1-26.

1312 Ramm, S., Todorov, P., Chandrasekaran, V., Dohman, A., Monteiro, M.B., Pavkovic, M., Muhlich, J.,
1313 Shankaran, H., Chen, W.W., Mettetal, J.T., Vaidya, V.S., 2019. A Systems Toxicology Approach for
1314 the Prediction of Kidney Toxicity and Its Mechanisms In Vitro. Toxicol Sci **169**, 54-69.

1315 Richard, A.M., Judson, R.S., Houck, K.A., Grulke, C.M., Volarath, P., Thillainadarajah, I., Yang, C.,
1316 Rathman, J., Martin, M.T., Wambaugh, J.F., Knudsen, T.B., Kancherla, J., Mansouri, K., Patlewicz,

1317 G., Williams, A.J., Little, S.B., Crofton, K.M., Thomas, R.S., 2016. ToxCast Chemical Landscape:
1318 Paving the Road to 21st Century Toxicology. *Chem Res Toxicol* **29**, 1225-1251.

1319 Ring, C.L., Arnot, J.A., Bennett, D.H., Egeghy, P.P., Fantke, P., Huang, L., Isaacs, K.K., Jolliet, O., Phillips,
1320 K.A., Price, P.S., Shin, H.-M., Westgate, J.N., Setzer, R.W., Wambaugh, J.F., 2019. Consensus
1321 Modeling of Median Chemical Intake for the U.S. Population Based on Predictions of Exposure
1322 Pathways. *Environmental Science & Technology* **53**, 719-732.

1323 Ring, C.L., Pearce, R.G., Setzer, R.W., Wetmore, B.A., Wambaugh, J.F., 2017. Identifying populations
1324 sensitive to environmental chemicals by simulating toxicokinetic variability. *Environ Int* **106**,
1325 105-118.

1326 Roed-Petersen, J., Batsberg, W., Larsen, E., 1990. Contact dermatitis from Naphthol AS. *Contact*
1327 *Dermatitis* **22**, 161-163.

1328 Rohban, M.H., Fuller, A.M., Tan, C., Goldstein, J.T., Syangtan, D., Gutnick, A., DeVine, A., Nijssure, M.P.,
1329 Rigby, M., Sacher, J.R., Corsello, S.M., Peppler, G.B., Bogaczynska, M., Boghossian, A., Ciotti,
1330 G.E., Hands, A.T., Mekareeya, A., Doan, M., Gale, J.P., Derynck, R., Turbyville, T., Boerckel, J.D.,
1331 Singh, S., Kiessling, L.L., Schwarz, T.L., Varelas, X., Wagner, F.F., Kafri, R., Eisinger-Mathason,
1332 T.S.K., Carpenter, A.E., 2022. Virtual screening for small-molecule pathway regulators by image-
1333 profile matching. *Cell Syst* **13**, 724-736 e729.

1334 Rohban, M.H., Singh, S., Wu, X., Berthet, J.B., Bray, M.A., Shrestha, Y., Varelas, X., Boehm, J.S.,
1335 Carpenter, A.E., 2017. Systematic morphological profiling of human gene and allele function via
1336 Cell Painting. *Elife* **6**.

1337 Schneidewind, T., Brause, A., Pahl, A., Burhop, A., Mejuch, T., Sievers, S., Waldmann, H., Ziegler, S., 2020.
1338 Morphological Profiling Identifies a Common Mode of Action for Small Molecules with Different
1339 Targets. *Chembiochem* **21**, 3197-3207.

1340 Seal, S., Carreras-Puigvert, J., Trapotsi, M.A., Yang, H., Spjuth, O., Bender, A., 2022. Integrating cell
1341 morphology with gene expression and chemical structure to aid mitochondrial toxicity
1342 detection. *Commun Biol* **5**, 858.

1343 Sheffield, T., Brown, J., Davidson, S., Friedman, K.P., Judson, R., 2021. tcplfit2: an R-language general
1344 purpose concentration-response modeling package. *Bioinformatics*.

1345 Simm, J., Klambauer, G., Arany, A., Steijaert, M., Wegner, J.K., Gustin, E., Chupakhin, V., Chong, Y.T.,
1346 Vialard, J., Buijnsters, P., Velter, I., Vapirev, A., Singh, S., Carpenter, A.E., Wuyts, R., Hochreiter,
1347 S., Moreau, Y., Ceulemans, H., 2018. Repurposing High-Throughput Image Assays Enables
1348 Biological Activity Prediction for Drug Discovery. *Cell Chem Biol* **25**, 611-618 e613.

1349 Srivastava, P., Panda, D., 2007. Rotenone inhibits mammalian cell proliferation by inhibiting microtubule
1350 assembly through tubulin binding. *The FEBS Journal* **274**, 4788-4801.

1351 Su, R., Xiong, S., Zink, D., Loo, L.H., 2016. High-throughput imaging-based nephrotoxicity prediction for
1352 xenobiotics with diverse chemical structures. *Arch Toxicol* **90**, 2793-2808.

1353 Svenningsen, E.B., Poulsen, T.B., 2019. Establishing cell painting in a smaller chemical biology lab - A
1354 report from the frontier. *Bioorg Med Chem* **27**, 2609-2615.

1355 Thomas, R.S., Bahadori, T., Buckley, T.J., Cowden, J., Deisenroth, C., Dionisio, K.L., Frithsen, J.B., Grulke,
1356 C.M., Gwinn, M.R., Harrill, J.A., Higuchi, M., Houck, K.A., Hughes, M.F., Hunter, E.S., Isaacs, K.K.,
1357 Judson, R.S., Knudsen, T.B., Lambert, J.C., Linnenbrink, M., Martin, T.M., Newton, S.R., Padilla, S.,
1358 Patlewicz, G., Paul-Friedman, K., Phillips, K.A., Richard, A.M., Sams, R., Shafer, T.J., Setzer, R.W.,
1359 Shah, I., Simmons, J.E., Simmons, S.O., Singh, A., Sobus, J.R., Strynar, M., Swank, A., Tornero-
1360 Valez, R., Ulrich, E.M., Villeneuve, D.L., Wambaugh, J.F., Wetmore, B.A., Williams, A.J., 2019. The
1361 Next Generation Blueprint of Computational Toxicology at the U.S. Environmental Protection
1362 Agency. *Toxicol Sci* **169**, 317-332.

1363 Trapotsi, M.A., Mervin, L.H., Afzal, A.M., Sturm, N., Engkvist, O., Barrett, I.P., Bender, A., 2021.
1364 Comparison of Chemical Structure and Cell Morphology Information for Multitask Bioactivity
1365 Predictions. *J Chem Inf Model* **61**, 1444-1456.

1366 Uhlen, M., Zhang, C., Lee, S., Sjostedt, E., Fagerberg, L., Bidkhori, G., Benfeitas, R., Arif, M., Liu, Z., Edfors,
1367 F., Sanli, K., von Feilitzen, K., Oksvold, P., Lundberg, E., Hober, S., Nilsson, P., Mattsson, J.,
1368 Schwenk, J.M., Brunnstrom, H., Glimelius, B., Sjoblom, T., Edqvist, P.H., Djureinovic, D., Micke,
1369 P., Lindskog, C., Mardinoglu, A., Ponten, F., 2017. A pathology atlas of the human cancer
1370 transcriptome. *Science* **357**.

1371 Vaughan, A., Guilbault, G.G., Hackney, D., 1971. Fluorometric methods for analysis of acid and alkaline
1372 phosphatase. *Anal Chem* **43**, 721-724.

1373 Wang, S.-H., Liang, C.-T., Liu, Y.-W., Huang, M.-C., Huang, S.-C., Hong, W.-F., Su, J.-G.J., 2009. Crosstalk
1374 between activated forms of the aryl hydrocarbon receptor and glucocorticoid receptor.
1375 *Toxicology* **262**, 87-97.

1376 Warchal, S.J., Dawson, J.C., Carragher, N.O., 2019. Evaluation of Machine Learning Classifiers to Predict
1377 Compound Mechanism of Action When Transferred across Distinct Cell Lines. *Slas Discovery* **24**,
1378 224-233.

1379 Way, G.P., Kost-Alimova, M., Shibue, T., Harrington, W.F., Gill, S., Piccioni, F., Becker, T., Shafqat-Abbasi,
1380 H., Hahn, W.C., Carpenter, A.E., Vazquez, F., Singh, S., 2021. Predicting cell health phenotypes
1381 using image-based morphology profiling. *Mol Biol Cell* **32**, 995-1005.

1382 Way, G.P., Natoli, T., Adeboye, A., Litichevskiy, L., Yang, A., Lu, X., Caicedo, J.C., Cimini, B.A., Karhohs, K.,
1383 Logan, D.J., Rohban, M.H., Kost-Alimova, M., Hartland, K., Bornholdt, M., Chandrasekaran, S.N.,
1384 Haghighi, M., Weisbart, E., Singh, S., Subramanian, A., Carpenter, A.E., 2022. Morphology and
1385 gene expression profiling provide complementary information for mapping cell state. *Cell Syst*
1386 **13**, 911-923 e919.

1387 Williams, A.J., Grulke, C.M., Edwards, J., McEachran, A.D., Mansouri, K., Baker, N.C., Patlewicz, G., Shah,
1388 I., Wambaugh, J.F., Judson, R.S., Richard, A.M., 2017. The CompTox Chemistry Dashboard: a
1389 community data resource for environmental chemistry. *J Cheminform* **9**, 61.





1390 Willis, C., Nyffeler, J., Harrill, J.A., 2020. Phenotypic Profiling of Reference Chemicals Across Biologically
1391 Diverse Cell Types Using the Cell Painting Assay, *SLAS Discovery*, pp.

1392 Woehrmann, M.H., Bray, W.M., Durbin, J.K., Nisam, S.C., Michael, A.K., Glassey, E., Stuart, J.M., Lokey,
1393 R.S., 2013. Large-scale cytological profiling for functional analysis of bioactive compounds.
1394 *Molecular BioSystems* **9**, 2604-2617.

1395 Yang, C.H., Tarkhov, A., Maruszyk, J., Bienfait, B., Gasteiger, J., Kleinoeder, T., Magdziarz, T., Sacher, O.,
1396 Schwab, C.H., Schwoebel, J., Terfloth, L., Arvidson, K., Richard, A., Worth, A., Rathman, J., 2015.
1397 New Publicly Available Chemical Query Language, CSRML, To Support Chemotype
1398 Representations for Application to Data Mining and Modeling. *J Chem Inf Model* **55**, 510-528.

1399 Young, D.W., Bender, A., Hoyt, J., McWhinnie, E., Chirn, G.-W., Tao, C.Y., Tallarico, J.A., Labow, M.,
1400 Jenkins, J.L., Mitchison, T.J., Feng, Y., 2008. Integrating high-content screening and ligand-target
1401 prediction to identify mechanism of action. *Nature Chemical Biology* **4**, 59-68.




1402

A**B****D****C****E****13 phys-chem properties**

- average mass
- atmospheric hydroxylation rate
- bioconcentration factor
- biodegradation half-life
- boiling point
- Henry's law
- OPERA KM days
- octanol air partition
- soil adsorption coefficient
- octanol water partition
- melting point
- vapor pressure
- water solubility


		Predicted	
		Inactive	active
HTPP	Inactive	529	110
	Active	160	365






76% Balanced Accuracy




A**B****C**

- A 1,10-Phenanthroline
- B 1,2-Dibromo-2,4-dicyanobutane
- C 2-(Morpholin-4-ylidithio)-1,3-benzothiazole
- D 2-Ethylhexyl 4-(dimethylamino)benzoate
- E 2,5-Di-tert-butylbenzene-1,4-diol
- F 3-Hydroxy-2-naphthanilide
- G 4-Chloro-3,5-dimethylphenol
- H 4-Cumylphenol
- I all-trans-Retinoic acid
- J Arotinoid acid
- K Benzo(a)pyrene
- L Benzo(k)fluoranthene
- M Cyazofamid
- N Dexamethasone
- O Etoposide
- P Gentian Violet
- Q Octinoxate
- R Sodium dimethylthiocarbamate


BER






A**B****C**


A Primary screen




B Secondary screen











Biological similarity



C Orthogonal assay



A**B****C****D****#22: Organochlorines****E****F****#23: Chloroacetamide herbicides****G****#13: Plasticizer****H****#15: Food additives and flavors****Structural similarity****Biological similarity**